Curis (CRIS) 10-K24 Feb 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 18, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CRIS
Entity Registrant Name	CURIS INC
Entity Central Index Key	1108205
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		103,178,454
Entity Public Float			$120,126

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$7,747,411	$9,591,487
Investments	42,002,782	48,588,135
Short-term investment-restricted	13,877	13,877
Accounts receivable	1,960,995	1,477,188
Prepaid expenses and other current assets	489,844	495,260
Total current assets	52,214,909	60,165,947
Property and equipment, net	407,738	445,655
Long-term investments	788,768	10,726,685
Long-term investment-restricted	152,610	166,487
Goodwill	8,982,000	8,982,000
Other assets	67,544	104,034
Total assets	62,613,569	80,590,808
Current Liabilities:
Accounts payable	2,349,183	2,036,864
Accrued liabilities	2,007,699	1,911,479
Current portion of long-term debt, net	5,709,985	2,610,174
Total current liabilities	10,066,867	6,558,517
Long-term debt, net	22,589,058	27,945,186
Warrants		716,786
Other long-term liabilities	174,018	196,734
Total liabilities	32,829,943	35,417,223
Commitments (Note 8)
Stockholders' Equity:
Common stock, $0.01 par value-225,000,000 shares authorized at December 31, 2014 and 2013, respectively; 87,253,657 shares issued and 86,030,811 shares outstanding at December 31, 2014; 87,081,862 shares issued and 85,859,016 shares outstanding at December 31, 2013	872,537	870,819
Additional paid-in capital	810,001,410	806,660,340
Treasury stock (at cost, 1,222,846 shares at December 31, 2014 and 2013, respectively)	-1,524,029	-1,524,029
Accumulated deficit	-779,555,295	-760,826,561
Accumulated other comprehensive loss	-10,997	-6,984
Total stockholders' equity	29,783,626	45,173,585
Total liabilities and stockholders' equity	$62,613,569	$80,590,808

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares issued	87,253,657	87,081,862
Common stock, shares outstanding	86,030,811	85,859,016
Treasury stock, at cost	1,222,846	1,222,846

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
License fees	$3,000,000	$10,000,000	$14,000,000
Royalties	6,757,023	3,942,136	1,529,644
Research and development, net	86,458	1,059,896	1,442,347
Total revenues	9,843,481	15,002,032	16,971,991
Costs and Expenses:
Cost of royalties	339,578	197,796	176,482
Research and development	13,659,398	12,926,834	15,492,302
In-process research and development			9,500,000
General and administrative	11,706,754	11,293,811	10,423,014
Total costs and expenses	25,705,730	24,418,441	35,591,798
Loss from operations	-15,862,249	-9,416,409	-18,619,807
Other Income (Expense):
Interest income	165,103	164,650	149,937
Interest expense	-3,748,374	-3,841,646	-204,167
Change in fair value of warrant liability	716,786	771,393	2,257,130
Total other (expense) income	-2,866,485	-2,905,603	2,202,900
Net loss	-18,728,734	-12,322,012	-16,416,907
Net Loss per Common Share (Basic and Diluted)	($0.22)	($0.15)	($0.21)
Weighted Average Common Shares (Basic and Diluted)	85,974,535	82,339,493	79,059,153
Net loss	-18,728,734	-12,322,012	-16,416,907
Other comprehensive loss, net of tax:
Unrealized loss on marketable securities	-4,013	-22,143	-18,806
Comprehensive loss	($18,732,747)	($12,344,155)	($16,435,713)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]
Balance at Dec. 31, 2011	$39,875,957	$781,654	$772,039,254	($891,274)	($732,087,642)	$33,965
Balance, shares at Dec. 31, 2011		78,165,360
Other issuances of common stock	6,239,343	27,001	6,212,342
Other issuances of common stock, shares		2,700,128
Issuance of common stock to licensors	964,000	2,000	962,000
Issuance of common stock to licensors, shares		200,000
Recognition of employee stock-based compensation	3,268,689		3,268,689
Non-employee stock-based compensation expense, including mark-to-market	355,222		355,222
Other comprehensive loss	-18,806					-18,806
Net loss	-16,416,907				-16,416,907
Balance at Dec. 31, 2012	34,267,498	810,655	782,837,507	-891,274	-748,504,549	15,159
Balance, shares at Dec. 31, 2012		81,065,488
Other issuances of common stock	20,880,756	60,164	20,820,592
Other issuances of common stock, shares		6,191,513
Repurchase of Company common stock (see Note 2(i))	-632,755			-632,755
Repurchase of Company common stock, shares (see Note 2(i))		-175,139
Recognition of employee stock-based compensation	2,651,152		2,651,152
Non-employee stock-based compensation expense, including mark-to-market	351,089		351,089
Other comprehensive loss	-22,143					-22,143
Net loss	-12,322,012				-12,322,012
Balance at Dec. 31, 2013	45,173,585	870,819	806,660,340	-1,524,029	-760,826,561	-6,984
Balance, shares at Dec. 31, 2013	87,081,862	87,081,862
Other issuances of common stock	282,799	1,718	281,081
Other issuances of common stock, shares		171,795
Recognition of employee stock-based compensation	3,140,855		3,140,855
Non-employee stock-based compensation expense, including mark-to-market	-80,866		-80,866
Other comprehensive loss	-4,013					-4,013
Net loss	-18,728,734				-18,728,734
Balance at Dec. 31, 2014	$29,783,626	$872,537	$810,001,410	($1,524,029)	($779,555,295)	($10,997)
Balance, shares at Dec. 31, 2014	87,253,657	87,253,657

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Issuances of common stock upon the exercise of warrants and stock options, for purchases under the ESPP, and pursuant to sales of shares under the Company's ATM agreement, issuance costs	$641,052	$27,356
Issuances of common stock upon the exercise of warrants and stock options, for purchases under the ESPP, and pursuant to sales of shares under the Company's ATM agreement, fair value of warrants exercised		615,859
Common Stock [Member]
Issuances of common stock upon the exercise of warrants and stock options, for purchases under the ESPP, and pursuant to sales of shares under the Company's ATM agreement, issuance costs	641,052	27,356
Issuances of common stock upon the exercise of warrants and stock options, for purchases under the ESPP, and pursuant to sales of shares under the Company's ATM agreement, fair value of warrants exercised		615,859
Additional Paid-In Capital [Member]
Issuances of common stock upon the exercise of warrants and stock options, for purchases under the ESPP, and pursuant to sales of shares under the Company's ATM agreement, issuance costs	641,052	27,356
Issuances of common stock upon the exercise of warrants and stock options, for purchases under the ESPP, and pursuant to sales of shares under the Company's ATM agreement, fair value of warrants exercised		$615,859

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities:
Net loss	($18,728,734)	($12,322,012)	($16,416,907)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	155,083	141,522	126,537
Stock-based compensation expense	3,059,989	3,002,241	3,623,911
Issuance of common stock to licensees			964,000
Change in fair value of warrant liability	-716,786	-771,393	-2,257,130
Amortization of debt issuance costs	89,120	104,842	5,769
Non-cash interest (income)/expense	169,652	95,197	-434,763
Non-cash interest on debt	-713,968	713,968
Gain on sale of fixed assets	-1,750
Changes in operating assets and liabilities:
Accounts receivable	-483,807	-569,124	-865,997
Prepaid expenses and other assets	-2,409	-116,639	40,959
Accounts payable and accrued and other liabilities	360,866	181,821	20,316
Total adjustments	1,915,990	2,782,435	1,223,602
Net cash used in operating activities	-16,812,744	-9,539,577	-15,193,305
Cash Flows from Investing Activities:
Purchases of investments	-41,399,246	-65,827,658	-69,153,956
Sales/maturities of investments	57,748,851	52,349,212	46,214,044
Decrease in restricted cash/investments	13,877	13,918	41,632
Expenditures for property and equipment	-92,209	-153,009	-104,975
Proceeds from sale of fixed assets	1,750
Net cash provided by/(used in) investing activities	16,273,023	-13,617,537	-23,003,255
Cash Flows from Financing Activities:
Proceeds from issuance of common stock associated with offerings, net of issuance costs (see Note 9)		16,245,984	879,080
Proceeds from issuance of common stock under the Company's share-based compensation plans and warrant exercises	282,799	4,016,383	5,105,699
Payment of debt issuance costs		-261,475	-160,240
(Payments)/proceeds from Curis Royalty's debt	-1,587,154		30,000,000
Net cash (used by)/provided by financing activities	-1,304,355	20,000,892	35,824,539
Net decrease in cash and cash equivalents	-1,844,076	-3,156,222	-2,372,021
Cash and cash equivalents, beginning of period	9,591,487	12,747,709	15,119,730
Cash and cash equivalents, end of period	7,747,411	9,591,487	12,747,709
Supplemental cash flow data:
Cash paid for interest	4,386,109	2,913,999
Non-cash items:
Treasury stock		632,755
Receivable for issuances of common stock			14,366
Unpaid debt issuance costs			$261,475

Operations

Operations	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Operations	-1	OPERATIONS
	Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.
	The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways to develop drug candidates including CUDC-907, a dual histone deacetylase, or HDAC and phosphoinositide-3 kinase, or PI3K, inhibitor, CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins, and CUDC-305, a Heat Shock Protein 90, or HSP90, inhibitor. Erivedge^®, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.
	In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene, a specialized, discovery stage biotechnology company developing novel therapies to treat cancer and inflammatory diseases. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The first two programs under the collaboration are orally-available small molecule antagonists of programmed death ligand-1 (PD-L1) in the immuno-oncology field and orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field.
	The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.
	The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress it’s clinical development in indications other than BCC; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement, the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.
	The Company’s future operating results will largely depend on the magnitude of payments that it receives and makes under its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Genentech’s ongoing clinical trials; Aurigene’s ability to successfully discover and develop preclinically programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material outlicensing or collaboration agreements for its proprietary drug candidates.
	The Company anticipates that existing cash, cash equivalents and investments at December 31, 2014 should enable it to maintain current and planned operations into 2016. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	-2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

		(a)	USE OF ESTIMATES
	The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include revenue recognition, including estimates of the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the collectibility of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities, including our warrant liability. Actual results may differ from such estimates.

		(b)	CONSOLIDATION
	The accompanying consolidated financial statements include the Company and its wholly owned subsidiaries, Curis Royalty (see Note 7), Curis Securities Corporation, Inc. and Curis Pharmaceuticals (Shanghai) Co., Ltd., or Curis Shanghai. The Company has eliminated all intercompany transactions in each of the years ended December 31, 2014, 2013 and 2012.

		(c)	REVENUE RECOGNITION
	The Company’s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company’s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. The Company follows the provisions of the Financial Accounting Standards Board, or FASB, Codification Topic 605, Revenue Recognition.
	License Fees and Multiple Element Arrangements
	In January 2011, the Company adopted a new U.S. generally accepted accounting principles, or GAAP, accounting standard on a prospective basis which amends existing revenue recognition accounting guidance to provide accounting principles and application guidance on whether multiple deliverables exist, how the arrangement should be separated, and the consideration allocated. This new guidance eliminates the requirement to establish objective evidence of fair value of undelivered products and services and instead provides for separate revenue recognition based upon management’s best estimate of the selling price for an undelivered item when there is no vendor-specific objective evidence or third-party evidence to determine the fair value of the undelivered item.
	Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured and the Company has no further performance obligations under the license agreement. Multiple element arrangements, such as license and development arrangements are analyzed to determine whether the deliverables, which often include a license and performance obligations such as research and steering committee services, can be separated or whether they must be accounted for as a single unit of accounting in accordance with GAAP. The Company recognizes up-front license payments as revenue upon delivery of the license only if the license has stand-alone value. If the license is considered to not have stand-alone value, the arrangement would then be accounted for as a single unit of accounting and the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed.
	If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are determined to be performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.
	Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized. Revenue will be recognized using either a relative performance or straight-line method. The Company recognizes revenue using the relative performance method provided that the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and such performance obligations are provided on a best-efforts basis. Direct labor hours or full-time equivalents are typically used as the measure of performance. Revenue recognized under the relative performance method would be determined by multiplying the total payments under the contract, excluding royalties and payments contingent upon achievement of substantive milestones, by the ratio of level of effort incurred to date to estimated total level of effort required to complete the Company’s performance obligations under the arrangement. Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the relative performance method, as of each reporting period.
	If the Company cannot reasonably estimate the level of effort required to complete its performance obligations under an arrangement, the performance obligations are provided on a best-efforts basis and the Company can reasonably estimate when the performance obligation ceases or the remaining obligations become inconsequential and perfunctory, then the total payments under the arrangement, excluding royalties and payments contingent upon achievement of substantive milestones, would be recognized as revenue on a straight-line basis over the period the Company expects to complete its performance obligations. Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line basis, as of the period ending date.
	If the Company cannot reasonably estimate when its performance obligation either ceases or becomes inconsequential and perfunctory, then revenue is deferred until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.

	Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.
	Substantive Milestone Payments
	In April 2010, the FASB issued guidance on the milestone method for revenue recognition purposes. Previously, definitive guidance on when the use of the milestone method was appropriate did not exist. This guidance provides a framework of the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate.
	Collaboration agreements that contain substantive milestone payments are recognized upon achievement of the milestone only if:

		•		such milestone is commensurate with either of the following:

		a)	the Company’s performance to achieve the milestone (for example, the achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement); or

		b)	the enhancement of the value of the deliverable as a result of a specific outcome resulting from the Company’s performance to achieve the milestone (or substantive Company effort is involved in achieving the milestone);

		•		such milestone relates solely to past performance; and

		•		the amount of the milestone payment is reasonable relative to all deliverables and payment terms in the arrangement.
	Determination as to whether a payment meets the aforementioned conditions involves management’s judgment. If any of these conditions are not met, the resulting payment would not be considered a substantive milestone, and the resulting payment would be recognized as revenue as performance obligations are performed under either the relative performance or straight-line methods, as applicable, and in accordance with these policies as described above. In addition, the determination that one such payment was not a substantive milestone could prevent the Company from concluding that subsequent milestone payments were substantive milestones and, as a result, any additional milestone payments could also be considered part of the consideration for the single unit of accounting and would be recognized as revenue as such performance obligations are performed under either the relative performance or straight-line methods, as applicable. Milestones that are tied to regulatory approval are not considered probable of being achieved until such approval is received. Milestones tied to counter-party performance are not included in the Company’s revenue model until the performance conditions are met.
	Reimbursement of Costs
	Reimbursement of research and development costs by third party collaborators is recognized as revenue provided the Company has determined that it is acting primarily as a principal in the transaction according to the provisions outlined in the FASB Codification Topic 605-45, Revenue Recognition, Principal Agent Considerations, the amounts are determinable and collection of the related receivable is reasonably assured.
	Royalty Revenue
	Since the first quarter of 2012, the Company has recognized royalty revenues related to Genentech’s and Roche’s sales of Erivedge. Royalty revenue is recognized upon the sale of the related products based on contractual terms, provided that the royalty amounts are fixed or determinable, collection of the related receivable is reasonably assured and we have no remaining performance obligations under the arrangement. If royalties are received when the Company was remaining performance obligations, it expects to attribute the royalty payments to the services being provided under the arrangement and therefore to recognize such royalty payments as such performance obligations are performed under either the relative performance or straight line methods, as applicable, and in accordance with these policies as described above. The Company expects to recognize royalty revenue in future quarters from Genentech’s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Notes 3(a) and 7). However, Erivedge royalties will service Curis Royalty’s debt to BioPharma-II, and only amounts in excess of certain quarterly repayment caps, if any, will be available to the Company for use in operations.
	Deferred Revenue
	Amounts received prior to satisfying the above revenue recognition criteria are recorded as short term deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized during the year ending December 31, 2015 would be classified as long-term deferred revenue. As of December 31, 2014 and 2013, the Company had no amounts classified as short-term or long-term deferred revenue.
	Summary
	During the years ended December 31, 2014, 2013 and 2012, total gross revenues from the Company’s collaborators as a percent of total gross revenues of the Company were as follows:


			Year Ended December 31,
			2014				2013				2012
	Genentech			100	%			95	%			94	%
	LLS			—	%			4	%			6	%

		(d)	RESEARCH AND DEVELOPMENT
	Research and development expense consists of costs incurred to discover, research and develop drug candidates. These expenses consist primarily of: (1) salaries and related expenses for personnel including stock-based compensation expense; (2) outside service costs, including clinical research organizations and medicinal chemistry; (3) sublicense payments; and (4) the costs of supplies and reagents, consulting, and occupancy and depreciation charges. In addition, the Company incurred in-process research and development expenses of $9,500,000 during the year ended December 31, 2012, representing the one-time license and technology transfer fee related to the license of CUDC-427 from Genentech (see Note 3(b)). The Company expenses research and development costs as incurred.
	The Company recognizes cost of royalties on Erivedge royalty revenue earned under the June 2003 collaboration with Genentech related to obligations to third-party university licensors. The Company is also incurring research and development expenses under this collaboration related to the maintenance of these third-party licenses to certain background technologies. In addition, the Company records research and development expense for obligations to certain third-party university licensors upon earning payments from Genentech related to the achievement of clinical development and regulatory objectives under this collaboration.

		(e)	CASH EQUIVALENTS AND INVESTMENTS
	Cash equivalents consist of short-term, highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. The Company’s short-term investments are marketable securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable securities with original maturities of greater than twelve months from the balance sheet. Marketable securities consist of commercial paper, corporate bonds and notes, and government obligations. All of the Company’s investments have been designated as available-for-sale and are stated at fair value with any unrealized holding gains or losses included as a component of stockholders’ equity and any realized gains and losses recorded in the statement of operations in the period the securities are sold.
	Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Realized gains and losses, dividends and interest income are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
	The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2014 are as follows:


			Amortized				Unrealized				Unrealized				Fair Value
			Cost				Gain				Loss				Fair Value
	Corporate bonds and notes—short-term		$	42,011,286			$	4,883			$	(13,387	)		$	42,002,782
	Corporate bonds and notes—long-term			791,261				—				(2,493	)			788,768

	Total investments		$	42,802,547			$	4,883			$	(15,880	)		$	42,791,550

Short-term investments have maturities ranging from one and twelve months with a weighted average maturity of 4.1 months. Long-term investments have maturities ranging from January 2016 to May 2016 with a weighted average maturity of 13.8 months.
The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of December 31, 2013 with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows:


		Amortized				Unrealized				Unrealized				Fair Value
		Cost				Gain				Loss				Fair Value
Corporate bonds and notes		$	47,091,593			$	9,036			$	(15,476	)		$	47,085,153
US government and municipal obligations			501,170				10				—			$	501,180

Total investments		$	47,592,763			$	9,046			$	(15,476	)		$	47,586,333

In addition, a certificate of deposit in the amount of $1,001,802 that the Company held as of December 31, 2013 was included within short-term investments in the consolidated balance sheet but is excluded from the table above as it was not deemed to be a security.
As of December 31, 2013, the Company also recorded long-term investments of $10,726,685 on its Consolidated Balance Sheet. This amount is comprised of corporate and government-secured debt securities with maturities ranging from January 2015 to May 2015 with a weighted average maturity of 14.3 months and with amortized cost totaling $10,727,958, less unrealized net losses of $1,273.

	(f)	FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP also defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact.

The FASB Codification Topic 820, Fair Value Measurements and Disclosures, requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:


Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s warrant liability was valued using a probability-weighted Black-Scholes model, discussed further in Note 9, and is therefore classified as Level 3.
In accordance with the fair value hierarchy, the following table shows the fair value as of December 31, 2014 and 2013 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at December 31, 2014 and 2013.


		Quoted Prices in				Other				Unobservable				Fair Value
		Active Markets				Observable				Inputs
		(Level 1)				Inputs				(Level 3)
						(Level 2)
As of December 31, 2014:
Cash equivalents
Money market funds		$	4,419,894			$	—			$	—			$	4,419,894
Municipal bonds			—				1,090,000				—				1,090,000
Short- and long-term investments
Corporate commercial paper, stock, bonds and notes			40,091,800				2,699,750				—				42,791,550

Total assets at fair value		$	44,511,694			$	3,789,750			$	—			$	48,301,444



		Quoted Prices in				Other				Unobservable				Fair Value
		Active Markets				Observable				Inputs
		(Level 1)				Inputs				(Level 3)
						(Level 2)
As of December 31, 2013:
Cash equivalents
Money market funds		$	5,535,716			$	—			$	—			$	5,535,716
Corporate commercial paper, bonds and notes			—				1,749,983				—				1,749,983
Municipal bonds			—				1,110,000				—				1,110,000
Short- and long-term investments
US government obligations			—				1,151,932				—				1,151,932
Corporate commercial paper, stock, bonds and notes			20,176,154				36,984,932				—				57,161,086

Total assets at fair value		$	25,711,870			$	40,996,847			$	—			$	66,708,717

Warrant liability			—				—				716,786				716,786

Total liabilities at fair value		$	—			$	—			$	716,786			$	716,786

The above table excludes a certificate of deposit in the amount of $1,001,802 that the Company held as of December 31, 2013.
The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the years ended December 31, 2014 and 2013:


Balance at December 31, 2012		$	1,488,179
Change in fair value			(771,393	)

Balance at December 31, 2013		$	716,786
Change in fair value			(716,786	)

Balance at December 31, 2014		$	—

The remaining 1,373,517 warrants outstanding as of December 31, 2014 expired unexercised in January 2015.

	(g)	LONG-LIVED ASSETS OTHER THAN GOODWILL
Long-lived assets other than goodwill consist of property and equipment. The aggregate net balances for these long-lived assets were $407,738 and $445,655 as of December 31, 2014 and 2013, respectively. The Company applies the guidance in FASB Codification Topic 360-10-05, Impairment or Disposal of Long-Lived Assets. If it were determined that the carrying value of the Company’s other long-lived assets might not be recoverable based upon the existence of one or more indicators of impairment, the Company would measure an impairment based on the difference between the carrying value and fair value of the asset. The Company did not recognize any impairment charges for the years ended December 31, 2014, 2013 or 2012.
Purchased equipment is recorded at cost. The Company does not currently hold any leased equipment. Depreciation and amortization are provided on the straight-line method over the estimated useful lives of the related assets or the remaining terms of the leases, whichever is shorter, as follows:


Asset Classification		Estimated Useful Life
Laboratory equipment, computers and software		3-5 years
Leasehold improvements		Lesser of life of the lease or the life of the asset
Office furniture and equipment		5 years

The Company incurred debt issuance costs totaling $421,715 in connection with the Curis Royalty loan transaction, of which $215,000 related to expenses that the Company paid to third parties on behalf of BioPharma-II and the remaining $206,715 were incurred directly by the Company. The debt issuance costs incurred directly by the Company were capitalized as assets and will be amortized over the estimated term of the debt using the straight-line. Assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires management to make estimates that could impact the Company’s short- and long-term classification of the debt issuance costs, as well as the period over which these costs will be amortized (see Note 7). As of December 31, 2014 and 2013, the Company had recorded short-term debt issuance costs of $43,616 and $51,441, respectively, and long-term debt issuance costs of $64,564 and $101,055, respectively. These costs are reported within the prepaid expenses and other current assets and other assets line items, respectively, in the Company’s Consolidated Balance Sheet at December 31, 2014 and 2013.

	(h)	GOODWILL
As of December 31, 2014 and 2013, the Company had recorded goodwill of $8,982,000. The Company applies the guidance in the FASB Codification Topic 350, Intangibles – Goodwill and Other. During each of December 2014, 2013 and 2012, the Company completed its annual goodwill impairment tests and determined that the Company represented a single reporting unit and as of those dates the fair value of the Company exceeded the carrying value of its net assets. Accordingly, no goodwill impairment was recognized for the years ended December 31, 2014, 2013 and 2012.

	(i)	TREASURY STOCK
On May 31, 2002, the Company announced that its Board of Directors had approved the repurchase of up to $3,000,000 of the Company’s common stock. The Company accounted for its common stock repurchases as treasury stock under the cost method. In 2002, the Company repurchased 1,047,707 shares of its common stock at a cost of $891,274 pursuant to this repurchase program.
The Company’s 2000 Stock Incentive Plan and the Amended and Restated 2010 Plan generally allow participants to purchase common stock upon the exercise of a stock option by delivery of shares of Company common stock held directly by the participant, with such shares of common stock valued at the closing price on the Nasdaq Global Market, or NASDAQ, on the date of exercise. During the year ended December 31, 2013, certain executive officers and a director exercised stock options by remitting shares of Curis common stock then held by the respective person. The Company accounted for the value of the common stock remitted to the Company in satisfaction of the exercise price as treasury stock under the cost method. These option holders remitted an aggregate of 175,139 shares during the year ended December 31, 2013 with an aggregate value equal to $632,755. As of December 31, 2014, the Company had repurchased an aggregate of 1,222,846 shares of its common stock at a total cost of $1,524,029.

	(j)	BASIC AND DILUTED LOSS PER COMMON SHARE
Basic and diluted net losses per share were determined by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, as the effect of the potential common stock equivalents is antidilutive due to the Company’s net loss position for all periods presented. Antidilutive securities consist of stock options and warrants outstanding as of the respective reporting period. Antidilutive securities as of December 31, 2014, 2013 and 2012 consisted of the following:


		For the Years Ended December 31,
		2014				2013				2012
Stock options outstanding			11,319,619				10,077,805				10,437,761
Warrants outstanding			1,373,517				1,373,517				1,373,517

Total antidilutive securities			12,693,136				11,451,322				11,811,278


	(k)	STOCK-BASED COMPENSATION
The Company adopted Statement of Financial Accounting Standards, or SFAS, No. 123 (revised 2004), Share-Based Payment (SFAS 123(R)), which established standards for the accounting of transactions in which an entity exchanges its equity instruments for goods or services, and is now referred to as the FASB Codification Topic 718, Compensation—Stock Compensation. Topic 718 focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. Topic 718 requires that the fair value of such equity instruments be recognized as an expense in the financial statements as services are performed.

	(l)	OPERATING LEASES
The Company currently has one facility located at 4 Maguire Road in Lexington, Massachusetts under a noncancellable operating lease agreement for office and laboratory space. The rent payments for this facility escalate over the lease term and the Company expenses its obligations under this lease agreement on a straight-line basis over the term of the lease (see Note 8(a)).

	(m)	CONCENTRATION OF RISK
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, short- and long-term investments. The Company invests directly in commercial paper of financial institutions and corporations with A-/Aa3 or better long-term ratings and A-1/P-1 short term debt ratings and U.S. Treasury securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s credit risk related to investments is reduced as a result of the Company’s policy to limit the amount invested in any one issue.
The Company’s accounts receivable at December 31, 2014, represents amounts due from collaborators, primarily for royalties earned on sales of Erivedge by Genentech and Roche.
The Company relies on third parties to supply certain raw materials necessary to produce its drug candidates, including CUDC-907 and CUDC-427, for preclinical studies and clinical trials. There are a small number of suppliers for certain raw materials that the Company uses to manufacture its drug candidates.

	(n)	COMPREHENSIVE LOSS
Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes unrealized holding gains and losses arising during the period on available-for-sale securities that are not other-than-temporarily impaired.

	(o)	NEW ACCOUNTING PRONOUNCEMENTS
In May 2014, the FASB issued guidance codified in ASC 606, Revenue Recognition—Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition, and is effective for public companies for fiscal years beginning after December 15, 2016. The Company is currently evaluating the impact of the provisions of ASC 606.
In August 2014, the FASB issued an accounting standards update, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which is included in ASC 205, Presentation of Financial Statements. This update provides an explicit requirement for management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The guidance will be effective for fiscal years beginning after December 15, 2016, and applied prospectively; early adoption is also permitted. The Company does not expect adoption of this guidance to have a material impact on its financial condition or results of operations.

	(p)	SEGMENT REPORTING
The Company is engaged solely in the discovery and development of innovative drug candidates for the treatment of human cancers. Accordingly, the Company has determined that it operates in one operating segment.

Research_and_Development_Colla

Research and Development Collaborations	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research and Development Collaborations	-3	RESEARCH AND DEVELOPMENT COLLABORATIONS

		(a)	GENENTECH, INC. JUNE 2003 COLLABORATION

		(i)	Agreement Summary
	In June 2003, the Company licensed its proprietary Hedgehog pathway technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge. Genentech is currently conducting a Phase 2 clinical trial with Erivedge in less severe basal cell carcinoma and several additional clinical trials are ongoing by third parties under collaboration agreements between Genentech and the National Cancer Institute as well as Genentech and other third-party investigators.
	The Company is eligible to receive up to $115,000,000 in contingent cash payments under the collaboration for the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. The Company has received $59,000,000 in contingent cash payments through December 31, 2014.
	In addition to these payments, the Company’s wholly-owned subsidiary, Curis Royalty, is entitled to a royalty on net sales of Erivedge that ranges from 5% to 7.5% based on worldwide annual net sales ranging from less than $150 million to $600 million. The royalty rate applicable to Erivedge may be decreased by 2% (such that the applicable royalty rate will range between 3% to 5.5%) in certain specified circumstances, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable regulatory authority and is being sold in such country by a third party for use in the same indication as Erivedge or when there is no issued intellectual property covering Erivedge in a territory in which sales are recorded. Future royalty payments related to Erivedge will service the outstanding debt and accrued interest to BioPharma-II, up to the quarterly caps for 2015, and until the debt is fully repaid thereafter (see Note 7).
	Unless terminated earlier, the agreement shall expire six months after the later of the expiration of Genentech’s obligation to pay royalties to the Company under the agreement or such time as no activities have occurred under the agreement for a period of twelve months.

		(ii)	Accounting Summary
	The Company considers its arrangement with Genentech to be a revenue arrangement with multiple deliverables. The Company’s deliverables under this collaboration include an exclusive license to its Hedgehog pathway inhibitor technologies, research and development services for the first two years of the collaboration, and participation on the joint steering committee. The Company applied the provisions of the FASB Codification Topic 605-25, Revenue Recognition, Multiple Element Arrangement to determine whether the performance obligations under this collaboration should be accounted for separately or should be accounted for as a single unit of account. The Company determined that the deliverables, specifically, the license, research and development services and steering committee participation, represented a single unit of account because the Company believes that the license, although delivered at the inception of the arrangement, did not have stand-alone value to Genentech without the Company’s research and development services and steering committee participation. During 2007, the Company reassessed its participation on the joint steering committee and concluded that its participation in the joint steering committee had become inconsequential and perfunctory. As a result, the Company determined that it had no further performance obligations under this collaboration and consideration received after this date is recognized in the Company’s financial statements in the period in which it was earned.
	The Company received contingent payments from Genentech totaling $3,000,000, $10,000,000 and $14,000,000 during the years ended December 31, 2014, 2013 and 2012, respectively, for the achievement of certain clinical and regulatory development objectives related to Erivedge described above. The Company has recorded these amounts as revenue within “License Fees” in the Revenues section of its Consolidated Statement of Operations for the years ended December 31, 2014, 2013 and 2012.
	As a result of its licensing agreements with various universities, the Company is obligated to make payments to these university licensors when certain payments are received from Genentech. Through December 31, 2014, the Company has incurred aggregate research and development expenses over the term of this collaboration of $4,364,000 related to payments made to these university licensors in connection with the Company’s receipt of cash payments from Genentech for research, development and regulatory objectives achieved related to such university licensing agreements. In connection with the receipt of payments from Genentech, the Company recorded research and development expenses of $2,114,000 during the year ended December 31, 2012, which represents the Company’s obligations to these university licensors. Of this amount, the Company recognized expense of $964,000, which represents the fair value of a one-time issuance of an aggregate of 200,000 shares of the Company’s common stock in March 2012 to two university licensors in connection with the FDA-approval of Erivedge in January 2012. In addition, the Company recorded research and development expenses of $650,000 for obligations the Company incurred in connection with Roche’s filing of an investigational new drug application in Australia and its application to the Therapeutic Goods Administration, or TGA, for marketing registration of Erivedge in Australia based on the $4,000,000 milestone that the Company received. The remaining expense recognized of $500,000 relates to the Company’s receipt of the $10,000,000 milestone payment associated with the FDA’s U.S. approval of Erivedge in January 2012. During the years ended December 31, 2014 and 2013, the Company recorded research and development expenses of $150,000 and $500,000, respectively, representing 5% of the total cash payments received during each year.
	In addition, the Company recognized $6,757,023, $3,942,136 and $1,529,644 in royalty revenue from Genentech’s net sales of Erivedge during the year ended December 31, 2014, 2013 and 2012, respectively. The Company also recorded $339,578, $197,796 and $176,482, respectively, as cost of royalty revenues within the costs and expenses section of its Consolidated Statements of Operations and Comprehensive Loss during these same periods. Cost of royalty revenues represents 5% of the royalties earned by Curis Royalty with respect to Erivedge that the Company is obligated to pay to university licensors. In addition to the 5% obligation, the Company made a one-time cash payment of $100,000 to one university licensor upon the first commercial sale of Erivedge during the year ended December 31, 2012.
	During the years ended December 31, 2014, 2013 and 2012, the Company also recognized “Research and development” revenue of $265,047, $291,448 and $363,000, respectively, related to expenses incurred on behalf of Genentech that were paid by the Company and for which Genentech is obligated to reimburse the Company. During the year ended December 31, 2014, Genentech incurred expenses of $225,707 under this collaboration which the Company is obligated to reimburse to Genentech, and which the Company has recorded as contra-revenues which have been net against research and development revenues in its Consolidated Statements of Operations and Comprehensive Loss. The Company will continue to recognize revenue for expense reimbursement as such reimbursable expenses are incurred, provided that the provisions of the FASB Codification Topic 605-45 are met.
	The Company had recorded as amounts receivable from Genentech under this collaboration, comprised primarily of Erivedge royalties earned in the fourth quarters of 2014 and 2013, of $1,958,000 and $1,455,000, as of December 31, 2014 and 2013, respectively, in “Accounts receivable” in the Company’s Current Assets section of its Consolidated Balance Sheets.

		(b)	IAP LICENSE AGREEMENT WITH GENENTECH, INC.
	On November 27, 2012, the Company entered into an exclusive license agreement, or the IAP license agreement, with Genentech, pursuant to which Genentech granted to the Company an exclusive, worldwide license to develop and commercialize CUDC-427.
	Pursuant to the terms of the IAP license agreement, Genentech transferred to the Company know how, information and materials necessary to continue the development of CUDC-427. Genentech also assigned its existing investigational new drug application, or IND, for CUDC-427 to the Company.
	Under the terms of the agreement, the Company agreed to use commercially reasonable efforts to develop and commercialize CUDC-427, including to conduct at least one additional Phase 1 clinical trial of CUDC-427, and unless the results of the additional Phase 1 trial do not provide sufficient scientific or clinical justification for continued clinical development, to conduct a Phase 2 clinical trial to inform a decision to start a Phase 3 clinical trial. The Company is solely responsible for all future costs related to the development, registration and commercialization of products under the agreement.
	Under the terms of the IAP agreement, the Company made a payment of $9,500,000 to Genentech as an up-front license fee and for technology transfer costs. Given that the compound licensed from Genentech is in clinical development and will require substantial development, regulatory and marketing approval efforts in order to reach technological feasibility, the Company recognized in-process research and development expense of $9,500,000 within the 2012 Consolidated Statement of Operations and Comprehensive Loss.
	In addition, Genentech is eligible to receive milestone payments upon the first commercial sale of products containing CUDC-427 in certain territories, and escalating royalties on net sales of products, which royalties are subject to reduction in certain limited circumstances. On a product-by-product and country-by-country basis, the term of the Company’s royalty payment obligations will begin on the first commercial sale of a product in a country and will continue until the later of (i) 10 years after the first commercial sale of such product in such country and (ii) the date of expiration of Genentech’s patent rights covering such product in such country. Upon expiration of its royalty payment obligations with respect to a product in a country, the Company’s license with respect to such product in such country will become royalty-free and fully paid-up.
	The IAP license agreement will continue in effect until expiration of all royalty payment obligations with respect to any product, unless terminated early by either party as described below. Upon expiration of the agreement, the Company’s license will become royalty-free, fully paid-up, irrevocable and perpetual.
	Each of Genentech and the Company may terminate the IAP license agreement prior to expiration in the event of the uncured material breach of the agreement by the other party. In addition, the Company may terminate the IAP license agreement prior to expiration for any reason upon 90 days’ prior written notice to Genentech. Upon any termination of the IAP license agreement, the license granted to the Company will terminate and revert to Genentech. If Genentech terminates the IAP license agreement for an uncured material breach by the Company, or if the Company terminates the agreement for any reason other than uncured material breach by Genentech, Genentech will be entitled to certain licenses and other rights with respect to products existing as of the date of termination, and the Company may, under specified circumstances, be obligated to supply products to Genentech for a limited period after termination.

		(c)	THE LEUKEMIA & LYMPHOMA SOCIETY AGREEMENT

		(i)	Agreement Summary
	In November 2011, the Company entered into an agreement under which The Leukemia & Lymphoma Society (LLS) agreed to support the Company’s ongoing development of CUDC-907 for patients with relapsed or refractory lymphoma and multiple myeloma. Under the agreement, LLS will make milestone payments up to $4,000,000 that are contingent upon the Company’s achievement of specified clinical development objectives with CUDC-907. Since the inception of the agreement through December 31, 2014, the Company has received $1,650,000 from LLS related to milestones achieved under this agreement. Additional milestone payments may be earned assuming CUDC-907 continues to progress through the Phase 1 clinical trial.
	Under certain conditions associated with the Company’s successful partnering and/or commercialization of CUDC-907 in the specified indications, the Company may be obligated to make payments, including royalties, to LLS of up to $10,000,000. This obligation is capped at 2.5 times the amount the Company receives from LLS, and, as of December 31, 2014, the maximum obligation, assuming that CUDC-907 successfully progresses through future clinical trials, would be $4,125,000. If clinical development of CUDC-907 does not continue to meet its clinical safety endpoints in future clinical trials in the defined field or fails to obtain necessary regulatory approvals, all funding provided to the Company by LLS will be considered a non-refundable grant. As of December 31, 2014, the Company has not recorded an obligation to repay any of the funds received from LLS because the contingent repayment obligation depends solely on the successful results of the continued development of CUDC-907, which is not probable at December 31, 2014 as this program remains in the very early stages of clinical development.
	The LLS agreement also stipulates a “follow-up diligence period” beginning on the date the Company receives its last milestone payment from LLS and ends on the earlier of (a) five years from that date or (b) the fulfillment (or termination, as applicable) of Company’s payment obligations as described above. During the follow-up period, the Company agrees that it will take the appropriate steps as are commercially reasonable to further the clinical and commercial development of CUDC-907 in the defined field in at least one major market, provided that the Company reasonably believes that CUDC-907 is safe and effective in the field as determined by successfully meeting its pre-determined endpoints in its clinical trials, and further provided that the Company receives necessary regulatory guidance from agency officials in the applicable major market(s) to continue development and reach the market for CUDC-907 in the defined field. If the program is successful as defined by the agreement, and if Curis cannot fund the additional clinical development, the Company agrees to seek to license CUDC-907 to a third party, either on its own or through LLS, in the defined field in the same commercially reasonable manner during the remainder of the follow-up period. The Company will be solely responsible for all costs related to the development, registration and commercialization of products under the agreement.
	The agreement became effective on November 29, 2011 and will remain in effect until the completion of the defined milestones, unless earlier terminated in accordance with the provisions of the agreement, including safety issues related to the administration of CUDC-907, failure to obtain or maintain regulatory approvals for clinical trials, and breach by either party.

		(ii)	Accounting Summary
	The Company considers its agreement with LLS to be a revenue arrangement with multiple deliverables. The Company’s obligations under this agreement include: (i) conduct the development program through a Phase Ib/IIa clinical trial; (ii) participate on the joint research advisory committee; and (iii) continue development during a follow-up diligence period of five years, if CUDC-907 is successful, as described above. The Company determined that the LLS arrangement is an obligation to perform contractual services and that payments received from LLS should be recognized as revenue rather than contra-research and development expenses or other income because this arrangement is part of the Company’s on-going operations as it relates to one of its three internal proprietary programs and the arrangement is similar to other types of arrangements the Company has entered into historically.
	The follow-up diligence period becomes an obligation only if and when CUDC-907 has successful results from the completion of a Phase 1b/2a study and has received the appropriate regulatory approvals to proceed with additional clinical testing. The Company initiated a Phase 1 study of CUDC-907 in December 2012 and treated the first patient with CUDC-907 in January 2013. Since the Company’s intention would be to continue to develop CUDC-907 upon completion of a successful program, either internally or through a licensee, it has determined that there is no commercial substance to the follow-up diligence period, which is also based on the same level of success of the program. As a result, the Company determined that the follow-up diligence period is a non-substantive obligation as: (i) this performance obligation is not essential to the current development of CUDC-907 as the Company is only eligible to receive funding if specified clinical development milestones are achieved; and (ii) any repayment right only exists if the program is successful beyond Phase 1b/2a and the Company breaches this obligation by choosing not to use reasonable effort to continue developing CUDC-907, which is not probable at December 31, 2014.
	The Company believes that its participation on the joint research advisory committee, which is comprised of equal representation from Curis and LLS, is tied to its performance to conduct the research program and is occurring concurrent with the research and development services. The Company determined that its participation on the joint research advisory committee does not have stand-alone value and is essential to the development of CUDC-907 since the Company has the sole responsibility for the development program. The Company determined that the only substantive deliverables are limited to the research and development services and joint research advisory committee participation, which represent a single unit of account.
	The Company applied the provisions of ASC 605-28, Revenue Recognition, Milestone Method to determine whether the revenue earned under this agreement should be accounted for as substantive milestones. In determining whether the milestones in this arrangement are substantive, the Company considered whether uncertainty exists as to: (i) the achievement of the milestone event at the inception of the arrangement; (ii) the achievement of the milestone involves substantive effort and can only be achieved based in whole or part on the performance or the occurrence of a specific outcome resulting from the Company’s performance; (iii) the amount of the milestone payment appears reasonable either in relation to the effort expected to be expended or to the projected enhancement of the value of the delivered items; (iv) there is any future performance required to earn the milestone; and (v) the consideration is reasonable relative to all deliverables and payment terms in the arrangement. When a substantive milestone is achieved, the accounting guidance permits recognition of revenue related to the milestone payment in its entirety. The Company determined that the milestones achieved in 2012 and 2013 under the LLS agreement were substantive and recognized related revenue totaling $650,000 and $1,000,000 in the years ended December 31, 2013 and 2012, respectively. The Company did not receive any milestones under this agreement during the year ended December 31, 2014.

Stock_Plans_and_Stock_Based_Co

Stock Plans and Stock Based Compensation	12 Months Ended
Stock Plans and Stock Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans and Stock Based Compensation	-4	STOCK PLANS AND STOCK BASED COMPENSATION
	As of December 31, 2014, the Company had two shareholder-approved, share-based compensation plans: (i) the Amended and Restated 2010 Stock Incentive Plan, or the Amended and Restated 2010 Plan, adopted by the Board of Directors in March 2013 and approved by shareholders in May 2013 and (ii) the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the Board of Directors in April 2010 and approved by shareholders in June 2010. In the first quarter of 2010, the Company’s 2000 Stock Incentive Plan expired in accordance with its terms and its 2000 Director Stock Option Plan had no available shares remaining under the plan. No additional awards will be made under these plans, although all outstanding awards under these plans will remain in effect until they are exercised or they expire in accordance with their terms.
	The Amended and Restated 2010 Stock Incentive Plan
	The Amended and Restated 2010 Plan permits the granting of incentive and non-qualified stock options and stock awards to employees, officers, directors, and consultants of the Company and its subsidiaries at prices determined by the Company’s Board of Directors. The Company can issue up to 9,000,000 shares of its common stock pursuant to awards granted under the Amended and Restated 2010 Plan. Options become exercisable as determined by the Board of Directors and expire up to 10 years from the date of grant. The Amended and Restated 2010 Plan uses a “fungible share” concept under which each share of stock subject to awards granted as options and stock appreciation rights (“SARs”), will cause one share per share under the award to be removed from the available share pool, while each share of stock subject to awards granted as restricted stock, restricted stock units, other stock-based awards or performance awards where the price charged for the award is less than 100% of the fair market value of the Company’s common stock will cause 1.3 shares per share under the award to be removed from the available share pool. As of December 31, 2014, the Company had only granted options to purchase shares of the Company’s common stock with an exercise price equal to the closing market price of the Company’s common stock on the NASDAQ Global Market on the grant date. As of December 31, 2014, 1,749,752 shares remained available for grant under the Amended and Restated 2010 Plan.
	During the year ended December 31, 2014, the Company’s board of directors granted options to purchase 2,040,500 shares of the Company’s common stock to officers and employees of the Company under the 2010 Plan. Of this amount, options to purchase 1,000,500 shares of common stock vest over a four-year period and bear exercise prices that are equal to the closing market price of the Company’s common stock on the NASDAQ Global Market on the grant dates. The remaining options to purchase 1,040,000 shares of common stock were issued to the Company’s officers and will vest in tranches only if the closing sale price of the Company’s common stock is maintained at specified levels for a period of 60 consecutive trading days prior to the third anniversary of the respective grant dates. If the specified market conditions are not achieved prior to the third anniversary of the respective grant dates, any unvested options will be forfeited and such shares will then be available for grant under the 2010 Plan.
	During the year ended December 31, 2014, the Company’s board of directors also granted options to its non-employee directors to purchase 235,000 shares of common stock under the 2010 Plan, which will vest monthly over a one-year period. All options granted to non-employee directors during the year ended December 31, 2014 bear exercise prices that are equal to the closing market price of the Company’s common stock on the NASDAQ Global Market on the grant date.

	Employee and Director Grants
	In determining the fair value of stock options, the Company uses the Black-Scholes option pricing model. The Black-Scholes option pricing model contained the following weighted average assumptions for employee option grants issued in each of the following years:


			For the Year Ended
			December 31,
			2014				2013				2012
	Expected term (years)—Employees			6				6				6
	Expected term (years)—Officers and Directors			7				7				6
	Risk-free interest rate			1.9	%			1.0-2.1	%			1.0-1.2	%
	Expected volatility			70-71	%			70-72	%			74-76	%
	Expected dividend yield			None				None				None
	The expected volatility is based on the annualized daily historical volatility of the Company’s stock price for a time period consistent with the expected term of each grant. Management believes that the historical volatility of the Company’s stock price best represents the volatility of the stock price. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the respective grant. The Company has not historically paid cash dividends, and does not expect to pay cash dividends in the foreseeable future.
	The stock price volatility and expected terms utilized in the calculation involve management’s best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.
	At December 31, 2014, the aggregate intrinsic value of employee options outstanding was $659,000, of which all related to exercisable options, and the weighted average remaining contractual life of vested stock options was 5.89 years. The weighted average grant-date fair values of stock options granted with standard vesting terms during the years ended December 31, 2014, 2013 and 2012 were $1.79, $2.27 and $2.99 per share of common stock underlying such stock options, respectively. As of December 31, 2014, there was approximately $4,720,000, including the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding under the Company’s 2000 Stock Incentive Plan and Amended and Restated 2010 Plan that is expected to be recognized as expense over a weighted average period of 2.4 years. The intrinsic value of employee stock options exercised during the years ended December 31, 2014, 2013 and 2012 were $105,000, $2,091,000 and $6,145,000, respectively. The total fair value of vested stock options for the years ended December 31, 2014, 2013 and 2012 were $2,907,000, $2,716,000 and $2,525,000, respectively.
	Vesting Tied to Market Conditions
	Monte Carlo simulation models were used to value stock options to purchase an aggregate of 1,040,000 shares of common stock granted to the Company’s officers during the year ended December 31, 2014. Of this amount, options to purchase 640,000 shares of common stock were granted in February 2014 with an exercise price of $3.09 and options to purchase 400,000 shares of common stock were granted in June 2014 with an exercise price of $1.75 per share that contained specific market conditions. The key assumptions used in these Monte Carlo simulation models and resulting valuations are noted in the following table:


			Market		Market
			Condition		Condition
			Options		Options
			Granted		Granted
			February 18,		June 2,
			2014		2014
	Expected life (years)—officers		6		6
	Risk-free interest rate		1.90%		2.10%
	Volatility		70%		65%
	Dividends		None		None
	Number of options granted		640,000		400,000
	Fair value per share		$1.20		$0.34
	Based on the above, the Monte Carlo simulation models calculated an aggregate fair value of $905,000, excluding forfeitures, related to these grants that are being recognized on a straight-line basis over the estimated vesting periods of the separate tranches. These awards accounted for $392,945 of the employee stock-based compensation expense recorded by the Company for the year ended December 31, 2014.
	Non-Employee Grants
	Pursuant to the Company’s stock plans, the Company has periodically granted stock options and unrestricted stock awards to consultants for services at the closing market price of the Company’s common stock on NASDAQ on the grant date. During the year ended December 31, 2013, the Company issued options to purchase a total of 525,000 shares of common stock to consultants. These options were issued pursuant to the Amended and Restated 2010 Plan at exercise prices equal to the closing market price of the Company’s common stock on NASDAQ on the grant date. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled. Unvested non-employee options are marked-to-market, which means that as the Company’s stock price fluctuates, the related expense either increases or decreases. The Company reversed previously recognized expense of $80,866 for the year ended December 31, 2014 and recognized expense of $351,089 and $355,222 related to non-employee stock options and stock awards for the years ended December 31, 2013 and 2012, respectively.
	A summary of stock option activity under the Amended and Restated 2010 Plan, the 2000 Stock Incentive Plan and the 2000 Director Stock Option Plan is summarized as follows:


			Number of				Weighted
			Shares				Average
							Exercise
							Price per
							Share
	Outstanding, December 31, 2013 (6,884,869 exercisable at weighted average price of $2.44 per share)			10,077,805			$	2.79
	Granted			2,275,500				2.65
	Exercised			(114,812	)			1.86
	Cancelled			(918,874	)			4.11

	Outstanding, December 31, 2014 (7,534,372 exercisable at weighted average price of $2.45 per share)			11,319,619			$	2.66

	Vested and unvested expected to vest			10,980,633			$	2.66

	2010 Employee Stock Purchase Plan
	The Company has reserved 500,000 of its shares of common stock for issuance under the ESPP. Eligible employees may purchase shares of the Company’s common stock at 85% of the lower closing market price of the common stock at the beginning or ending date of the purchase period, as defined. The Company has two six-month purchase periods per year. As of December 31, 2014, 325,314 shares were issued under the ESPP, of which 56,983 were issued during 2014. As of December 31, 2014, there were 174,686 shares available for future purchase under the ESPP.
	For the years ended December 31, 2014, 2013 and 2012, the Company recorded compensation expense related to its ESPP and calculated the fair value of shares expected to be purchased under the ESPP using the Black-Scholes models with the following assumptions:


			For the Year Ended December 31,
		2014				2013				2012
Compensation expense recognized under ESPP		$	25,604			$	40,008			$	72,833
Expected term			6 months				6 months				6 months
Risk-free interest rate			0.06-0.09	%			0.08-0.1	%			0.05-0.15	%
Volatility			55-66	%			42-66	%			42-75	%
Dividends			None				None				None
Stock-based compensation for employee and director stock option grants for the years ended December 31, 2014, 2013 and 2012 of $3,140,855, $2,651,152 and $3,268,689, respectively, was calculated using the above valuation models and has been included in the Company’s results of operations.
Total Stock-Based Compensation Expense
For the years ended December 31, 2014, 2013 and 2012, the Company recorded employee and non-employee stock-based compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations and Comprehensive Loss:


		For the Year Ended December 31,
		2014				2013				2012
Research and development expenses		$	671,063			$	879,052			$	1,075,134
General and administrative expenses			2,388,926				2,123,189				2,548,777

Total stock-based compensation expense		$	3,059,989			$	3,002,241			$	3,623,911

No income tax benefits have been recorded for the years ended December 31, 2014, 2013 or 2012, as the Company has recorded a full valuation allowance and management has concluded that it is more likely than not that the net deferred tax assets will not be realized (see Note 10).

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	-5	PROPERTY AND EQUIPMENT
	Property and equipment consist of the following:


			December 31,
			2014			2013
	Laboratory equipment, computers and software		$	1,963,017		$	1,941,588
	Leasehold improvements			62,621			62,621
	Office furniture and equipment			311,664			354,875

				2,337,302			2,359,084
	Less—Accumulated depreciation and amortization			(1,929,564	)		(1,913,429	)

	Total		$	407,738		$	445,655

	The Company recorded depreciation and amortization expense of $155,083, $141,522 and $126,537 for the years ended December 31, 2014, 2013 and 2012, respectively.
	During the years ended December 31, 2014, 2013 and 2012, the Company identified certain of its fully depreciated assets no longer being used. As a result, the Company wrote off gross assets and related accumulated depreciation, totaling $139,000, $329,000 and $418,000 for the years ended December 31, 2014, 2013 and 2012, respectively.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
Accrued Liabilities	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Accrued Liabilities	-6	ACCRUED LIABILITIES
	Accrued liabilities consist of the following:


			December 31,
			2014		2013
	Accrued compensation		$	1,386,226	$	1,267,954
	Professional fees			122,850		166,200
	Accrued interest on debt (see Note 7)			286,075		298,935
	Other			212,548		178,390

	Total		$	2,007,699	$	1,911,479

Debt

Debt	12 Months Ended
Debt	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	-7	DEBT
	In December 2012, Curis’ wholly-owned subsidiary, Curis Royalty, received a $30,000,000 loan at an annual interest rate of 12.25% pursuant to a credit agreement between Curis Royalty and BioPharma-II. In connection with the loan, Curis transferred to Curis Royalty its right to receive certain future royalty and royalty-related payments on the commercial sales of Erivedge that it may receive from Genentech. The loan and accrued interest will be repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is intended to be non-recourse to Curis. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i) escrow fees payable by Curis pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii) Curis’ royalty obligations to academic institutions, (iii) certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv) expenses incurred by Curis enforcing its right to indemnification under the collaboration agreement with Genentech. Remaining amounts, subject to caps of $3,000,000 per quarter in 2015, will be applied first to pay interest and second, principal on the loan. Curis Royalty will be entitled to receive the remaining royalty amounts above the caps, if any, and Curis remains entitled to receive any contingent payments upon achievement of clinical development objectives. Curis Royalty retains its right to royalty payments related to sales of Erivedge following repayment of the loan.
	The final maturity date of the loan will be the earlier of the date when the principal is paid in full or the termination of Curis Royalty’s right to receive royalties under the collaboration agreement with Genentech. At any time after January 1, 2017, Curis Royalty may, subject to certain limitations, prepay the outstanding principal of the loan in whole or in part, at a price equal to 105% of the outstanding principal on the loan, plus accrued but unpaid interest. The obligations of Curis Royalty under the credit agreement to repay the loan may be accelerated upon the occurrence of an event of default as defined in the credit agreement.

	Payments to BioPharma-II through December 31, 2014 totaled $8,901,330, of which $1,587,154 has been applied to the principal portion of the debt with the remainder applied to accrued interest, including interest capitalized and added to the principal portion of the loan during the year ended December 31, 2013. As of December 31, 2014, the Company recorded short- and long-term debt of $5,709,985 and $22,589,058, respectively (net of unamortized issuance costs of $38,074 and $75,729, respectively), and as of December 31, 2013, the Company recorded short- and long-term debt of $2,610,174 and $27,945,186, respectively (net of unamortized issuance costs of $53,503 and $105,105, respectively), related to the loan, with such amounts recorded within the Company’s Consolidated Balance Sheets. In addition, the Company recorded accrued interest payable on the debt of $286,075 and $298,935 as of December 31, 2014 and 2013, respectively, with such amounts included in the Company’s accrued liabilities section of its Consolidated Balance Sheets.
	Because the repayment of the term loan is contingent upon the level of Erivedge royalties received, the short- and long-term classification is based on the Company’s best estimate of the timing of amounts to be repaid and the repayment term may be shortened or extended depending on the actual level of Erivedge royalties. In addition, if Erivedge royalties are insufficient to pay the accrued interest on the outstanding loan, the unpaid interest outstanding will be added to the principal on a quarterly basis. Currently, Curis management estimates that the loan will be repaid in 2017. However, the actual repayment period could vary materially from the Company’s estimate to the extent that royalty payments it receives are lower than the Company’s current estimates, which could arise due to factors beyond the Company’s control, such as due to the sale of competing products that result in a lowering of the royalty rates we are entitled to receive, decreased market acceptance or a failure by Genentech and/or Roche to successfully commercialize Erivedge in territories where it has received regulatory approval. For example, Curis Royalty is currently entitled to a royalty on net sales of Erivedge that ranges from 5% to 7.5% based on worldwide annual net sales ranging from less than $150 million to $600 million. The royalty rate applicable to Erivedge may be decreased by 2% (such that the applicable royalty rate will range between 3% to 5.5%) in certain specified circumstances, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable regulatory authority and is being sold in such country by a third party for use in the same indication as Erivedge. The Company is aware of one competing Hedgehog pathway inhibitor that is currently under regulatory review in the United States and European Union. If this molecule is approved and commercialized, the royalty rate for sales in the applicable territory would decline and would likely increase our estimated repayment period.
	At December 31, 2014, the fair value of the principal portion of the debt is estimated as $28,710,000. Due to the assumptions required in estimating future Erivedge royalties, the expected repayment period and weighting of various royalty projection scenarios, determining the fair value of the debt required application of Level 3 inputs.
	The Company incurred debt issuance costs totaling $421,715 in connection with this loan transaction, of which $215,000 related to expenses that the Company paid on behalf of BioPharma-II and the remaining $206,715 were incurred directly by the Company. The debt issuance costs incurred directly by the Company were capitalized as assets and those costs paid on behalf of BioPharma-II have been netted against the debt and accrued interest in the Company’s Condensed Consolidated Balance Sheets as of December 31, 2014 and 2013 as detailed in the following table:


			As of
			December 31,
			2014			2013
	Other current assets		$	43,616		$	51,441
	Other assets			64,564			101,055

	Total debt issuance costs			108,180			152,496

	Debt, current			5,748,059			2,663,677
	Debt issue costs, current			(38,074	)		(53,503	)

	Debt, current portion net of issuance costs		$	5,709,985		$	2,610,174


	Debt, long-term			22,664,787			28,050,291
	Debt issue costs, long-term			(75,729	)		(105,105	)

	Debt, net of current portion and issuance costs		$	22,589,058		$	27,945,186

	All issuance costs are being amortized over the estimated term of the debt using the straight-line method which approximates the effective interest method. For the years ended December 31, 2014, 2013 and 2012, the Company recognized interest expense related to the loan with BioPharma-II of $3,748,374, $3,841,646 and $204,167 within the Company’s Consolidated Statement of Operations, comprised of interest accrued on the outstanding principal of the loan and amortization of debt issuance costs. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires management to make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized.
	Future payments of principal on the loan will require application of these same assumptions and will be used to estimate short- and long-term classification of the debt within the Company’s consolidated balance sheets, and these assumptions currently do not include a reduction in the Company’s forecasted royalties related to a competing product for the expected repayment term. As noted above, the Company is aware of one competing Hedgehog pathway inhibitor that is currently under regulatory review in the United States and European Union. If this molecule is approved and commercialized, the royalty rate for sales in the applicable territory would decline and would likely increase our estimated repayment period.
	At December 31, 2014, the Company estimates that its future payments of principal on the loan are as follows:


			Principal
	2015		$	5,748,059
	2016			10,011,236
	2017			12,653,551
	Thereafter			—

	Total payments			28,412,846

	Less current portion, gross			(5,748,059	)

	Total long-term debt obligations, gross		$	22,664,787

Commitments

Commitments	12 Months Ended
Commitments	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments	-8	COMMITMENTS

		(a)	OPERATING LEASES
	The Company is party to a lease agreement with the Trustees of Lexington Office Realty Trust pursuant to which the Company leases 24,529 square feet of property that is used for office, research and laboratory space located at 4 Maguire Road in Lexington, Massachusetts.
	The term of the 4 Maguire Road lease agreement commenced on December 1, 2010, and expires in February 2018. The Company has the option to extend the term for one additional five-year period upon the Company’s written notice to the lessor at least one year and no more than 18 months in advance of the extension.
	The total cash obligation for the base rent over the initial term of the lease agreement is approximately $4,401,000. In addition to the base rent, the Company is also responsible for its share of operating expenses and real estate taxes, in accordance with the terms of the lease agreement. The Company has provided a security deposit to the lessor in the form of an irrevocable letter of credit in the original amount of $277,546. The original deposit has been reduced throughout the lease term since its inception to $180,364 and $166,487 during 2013 and 2014, respectively, and will continue to be reduced an additional $13,877 in 2015, in accordance with the terms of the lease. These amounts have been classified as the restricted investments in the Company’s Consolidated Balance Sheet as of December 31, 2014 and 2013.
	The Company’s remaining operating lease commitments for all leased facilities with an initial or remaining term of at least one year are as follows:


	Year Ending December 31,
	2015		$	651,000
	2016			676,000
	2017			700,000
	2018			59,000

	Total minimum payments		$	2,086,000

	Rent expense for all operating leases was $614,000 for each of the years ended December 31, 2014, 2013 and 2012, respectively. The other long-term liability in the Company’s Consolidated Balance Sheet as of December 31, 2014 and 2013 represents the accrual for straight-line rent expense.

		(b)	LICENSE AGREEMENTS
	In exchange for the right to use licensed technology in its research and development efforts, the Company has entered into various license agreements. These agreements generally stipulate that the Company pay an annual license fee and is obligated to pay royalties on future revenues, if any, resulting from use of the underlying licensed technology. Such revenues may include, for example, up-front license fees, contingent payments upon collaborators’ achievement of development and regulatory objectives, and royalties. In addition, some of the agreements commit the Company to make contractually defined payments upon the attainment of scientific or clinical milestones. During the year ended December 31, 2012, the Company also issued 200,000 shares of its common stock under agreements with two of its university licensors resulting in expense of $964,000. The Company expenses these payments as incurred and expenses royalty payments as related future product sales or royalty revenues are recorded. The Company accrues expenses for scientific and clinical objectives over the period that the work required to meet the respective objective is completed, provided that the Company believes that the achievement of such objective is probable. The Company incurred license fee expenses within the “Research and development” line item of its “Costs and expenses” section of its Consolidated Statement of Operations for the years ended December 31, 2014, 2013 and 2012, of $417,000, $500,000, and $2,114,000, respectively. For the years ended December 31, 2014, 2013 and 2012, the Company also recognized $339,578, $197,796 and $176,482 as cost of royalty revenues in its Consolidated Statement of Operations related to such obligations (see Note 3(a)).
	During the year ended December 31, 2012, pursuant to the IAP license agreement with Genentech, the Company also recognized expense of $9,500,000 related to the up-front license fee and technology transfer costs within the in-process research and development expense line item of the Consolidated Statement of Operations (see Note 3(b)).

Common_Stock_and_Warrant_Liabi

Common Stock and Warrant Liability	12 Months Ended
Common Stock and Warrant Liability	Dec. 31, 2014
Text Block [Abstract]
Common Stock and Warrant Liability	-9	COMMON STOCK AND WARRANT LIABILITY

		(a)	2013 Sales Agreement with Cowen
	On July 3, 2013, the Company entered into a sales agreement with Cowen and Company, LLC, or Cowen, pursuant to which the Company may sell from time to time up to $30,000,000 of its common stock through an “at-the-market”, or ATM, equity offering program under which Cowen will act as sales agent. Subject to the terms and conditions of the sales agreement, Cowen may sell the common stock by methods deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NASDAQ, on any other existing trading market for the common stock or to or through a market maker other than on an exchange. In addition, with the Company’s prior written approval, Cowen may also sell the common stock by any other method permitted by law, including in negotiated transactions. Cowen will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of NASDAQ to sell on the Company’s behalf all of the shares requested to be sold by the Company. The Company has no obligation to sell any of the common stock under the sales agreement. Either the Company or Cowen may at any time suspend solicitations and offers under the sales agreement upon notice to the other party. The sales agreement may be terminated at any time by either the Company or Cowen upon written notice to the other party as specified in the sales agreement. The aggregate compensation payable to Cowen shall be 3% of the gross sales price of the common stock sold by Cowen pursuant to the sales agreement. In addition, the Company reimbursed $34,268 of Cowen’s expenses of Cowen in connection with the offering. Each party has agreed in the sales agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the sales agreement. Common stock will be issued pursuant to the Company’s currently-effective shelf registration statement on Form S-3. During the year ended December 31, 2013, the Company sold 3,850,206 shares of common stock under the sales agreement resulting in gross proceeds of $16,887,036. Total offering expenses incurred, including Cowen’s commission, related to the sales agreement through December 31, 2013 were $641,052, which offset the gross proceeds. No common stock was sold under this sales agreement during the year ended December 31, 2014.

		(b)	2011 At Market Issuance Sales Agreement with MLV
	On June 13, 2011, the Company entered into an ATM agreement with McNicoll, Lewis & Vlak LLC, or MLV, pursuant to which the Company could issue and sell from time to time up to $20,000,000 of its common stock through MLV in at-the-market and other specified forms of sale. The ATM Agreement terminated in June 2013 in accordance with the terms of the agreement
	During the year ended December 31, 2012, the Company sold 210,879 shares of common stock under the ATM agreement resulting in gross proceeds of $906,436. Total offering expenses, including MLV’s commission, incurred related to the ATM agreement for the year ended December 31, 2012, were $27,356, which offset the gross proceeds.

		(c)	2010 Registered Direct Offering
	On January 27, 2010, the Company completed a registered direct offering of 6,449,288 units with each unit consisting of (i) one share of the Company’s common stock and (ii) one warrant to purchase 0.25 of one share of common stock at a purchase price of $2.52 per unit. The Company received net proceeds from the sale of the units, after deducting offering expenses, of approximately $14,942,317 during the year ended December 31, 2010.
	In connection with this offering, the Company issued warrants to purchase an aggregate of 1,612,322 shares of common stock. As of December 31, 2014, warrants to purchase 238,805 shares of the Company’s common stock have been exercised, resulting in outstanding warrants to purchase an aggregate of 1,373,517 shares of common stock, all of which expired on January 27, 2015 pursuant to the terms of the warrants.
	The warrants had an initial exercise price of $3.55 per share and a five-year term. The warrants contained anti-dilution adjustment provisions that could have resulted in a decrease in the price and an increase in the number of shares of common stock issuable upon exercise of such warrants in the event of certain issuances of common stock by the Company at prices below $3.55 per share. Due to the original terms, the warrants were deemed to be a liability and, therefore, the fair values of the warrants were recorded as a liability in the Consolidated Balance Sheets as of December 31, 2014 and 2013. The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model under various probability-weighted outcomes which take into consideration the protective, but limited, cash-settlement feature of the warrants, with updated assumptions at each reporting date as detailed in the following table:


			As of December 31,
			2014			2013			2012
	Fair value of the warrants		$	—		$	716,786		$	1,488,179
	Expected term			0.1 years			1.1 years			2.1 years
	Risk-free interest rate			0	%		0.16	%		0.27	%
	Volatility			82	%		65	%		58	%
	Dividends			None			None			None
	The Company recorded other income of $716,786, $771,393 and $2,257,130 for the years ended December 31, 2014, 2013 and 2012, respectively, as a result of a change in the fair value of the warrant liability that was primarily due to changes in the Company’s stock price during the respective reporting periods. During the year ended December 31, 2012, as a result of the exercise of warrants to purchase 237,301 shares of the Company’s common stock, the warrant liability decreased by $615,859 with an offsetting increase to additional paid-in-capital.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	-10	INCOME TAXES
	For the years ended December 31, 2014, 2013 and 2012, the Company did not record any federal or state income tax expense given its continued operating losses.

	The provision for income taxes for continuing operations was at rates different from the U.S. federal statutory income tax rate for the following reasons:


			For the Year Ended
			December 31,
			2014			2013			2012
	Statutory federal income tax rate			34	%		34	%		34	%
	State income taxes, net of federal benefit			4.9	%		5.2	%		5.8	%
	Research and development tax credits			3.2	%		8.5	%		0.8	%
	Deferred compensation			(1.6	%)		0.8	%		2.1	%
	Interest expense			(1.6	%)		(2.5	%)		—	%
	Fair value of warrants			1.3	%		2.1	%		—	%
	NOL expirations			(2.8	%)		(5.2	%)		(36.0	%)
	Other			0.1	%		0.1	%		(1.7	%)
	Net decrease in valuation allowance			(37.5	%)		(43.0	%)		(5.0	%)

	Effective income tax rate			—	%		—	%		—	%

	Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.
	The principle components of the Company’s deferred tax assets at December 31, 2014 and 2013, respectively, are as follows:


			December 31,
			2014			2013
	Deferred Tax Assets:
	Net operating loss carryforwards		$	78,289,000		$	72,446,000
	Research and development tax credit carryforwards			12,212,000			11,588,000
	Depreciation and amortization			3,591,000			3,891,000
	Capitalized research and development expenditures			24,059,000			23,711,000
	Impairment of investments			120,000			120,000
	Stock options			3,534,000			2,723,000
	Accrued expenses and other			114,000			118,000
	Deferred interest expense			—			307,000

	Total Gross Deferred Tax Asset			121,919,000			114,904,000
	Valuation Allowance			(121,919,000	)		(114,904,000	)

	Net Deferred Tax Asset		$	—		$	—

	The classification of the above deferred tax assets is as follows:


			December 31,
			2014			2013
	Deferred Tax Assets:
	Current deferred tax assets		$	39,000		$	35,000
	Non-current deferred tax assets			121,880,000			114,869,000
	Valuation Allowance			(121,919,000	)		(114,904,000	)

	Net Deferred Tax Asset		$	—		$	—


	As of December 31, 2014, the Company had federal and state net operating losses, or NOLs, of $222,620,000 and $49,202,000, respectively, and federal and state research and experimentation credit carryforwards of approximately $9,807,000 and $3,644,000, respectively, which will expire at various dates starting in 2019 through 2034. The Company had $9,857,000 of Massachusetts net operating losses generated in 2009 that expired in 2014. As required by U.S. GAAP, the Company’s management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, and has determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. Accordingly, a valuation allowance of approximately $121,919,000 has been established at December 31, 2014. The benefit of deductions from the exercise of stock options is included in the NOL carryforwards. The benefit from these deductions will be recorded as a credit to additional paid-in capital if and when realized through a reduction of cash taxes.
	Utilization of the NOL and research and development, or R&D, credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company’s formation because the Company continues to maintain a full valuation allowance on its NOL and R&D credit carryforwards. In addition, there could be additional ownership changes in the future, which may result in additional limitations in the utilization of the carryforward NOLs and credits, and the Company does not expect to have any taxable income for the foreseeable future.
	An individual tax position must satisfy for some or all of the benefits of that position to be recognized in a company’s financial statements. At December 31, 2014 and 2013, the Company had no unrecognized tax benefits. The Company has not, as yet, conducted a study of its R&D credit carryforwards. This study may result in an adjustment to the Company’s R&D credit carryforwards, however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position under Topic 740. A full valuation allowance has been provided against the Company’s R&D credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required.
	The tax years 1999 through 2014 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S., as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service, or IRS, or state tax authorities if they have or will be used in a future period. The Company is currently not under examination by the IRS or any other jurisdictions for any tax years. The Company recognizes both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	-11	RELATED PARTY TRANSACTIONS


		(a)	Agreement with Former Officer

	On June 2, 2014, Daniel R. Passeri resigned as Chief Executive Officer of the Company. Mr. Passeri will continue to serve as a Class II director of the Company. On June 2, 2014, the Board of Directors of the Company elected Mr. Passeri Vice Chairman of the Board. As a non-employee director, Mr. Passeri will be compensated $100,000 per year plus meeting fees for his participation on the Board of Directors.

	The Company and Mr. Passeri entered into a consulting agreement on June 2, 2014. The agreement is for an initial term of one year, subject to renewal or earlier termination by the parties. Pursuant to the terms of the consulting agreement, Mr. Passeri has agreed to provide 120 hours per month of consulting services to the Company on intellectual property, corporate and strategic matters. In consideration for the services rendered by Mr. Passeri to the Company, the Company has agreed to pay Mr. Passeri $32,500 per month until June 1, 2015, provided that if at any time during the consultation period Mr. Passeri obtains full time employment with a third party, then Mr. Passeri and the Company will negotiate a good faith reduction in the number of hours that Mr. Passeri will consult, and thereafter Mr. Passeri will be paid an hourly fee, in lieu of the monthly retainer, for services rendered under the consulting agreement. On December 1, 2014, Mr. Passeri obtained full time employment with a third party.

	From June 2, 2014 until June 1, 2015, the consulting agreement may be terminated at any time by mutual agreement between the parties. The Company may terminate the consulting agreement immediately if Mr. Passeri breaches, or threatens to breach the terms of the non-disclosure and non-competition agreement previously entered into with the Company. Pursuant to the terms of the consulting agreement, the Company recognized expenses of $197,833 during the year ended December 31, 2014, under the consulting agreement.


		(b)	Agreement with Director

	On March 7, 2013, the Company’s Board of Directors elected Kenneth J. Pienta, M.D., to serve as a class I director until the 2015 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified. Dr. Pienta has served as a member of the Company’s Scientific Advisory Board since September 2006 and as its Chairman since June 2007, pursuant to the terms of a Scientific Advisory Board Agreement, or the SAB agreement, effective September 13, 2006, as amended from time to time, by and between Dr. Pienta and the Company. Pursuant to the SAB agreement, Dr. Pienta receives compensation in the amount of $50,000 per year, payable in equal quarterly installments. In addition, pursuant to the terms of a consulting agreement dated March 1, 2012, as amended from time to time, by and between the Company and Dr. Pienta, Dr. Pienta served as a consultant to the Company in the areas of corporate strategy and business development. The Company and Dr. Pienta terminated the consulting agreement in connection with his election as a member of the Board of Directors in March 2013. Pursuant to the terms of the SAB agreement and the consulting agreement, the Company paid cash consideration of $50,000, $72,258 and $190,000 during the years ended December 31, 2014, 2013 and 2012, respectively, as it relates to services provided by Dr. Pienta. In addition, the Company’s board of directors granted two options to purchase an aggregate of 125,000 shares of the Company’s common stock to Dr. Pienta in his role on the SAB. These options vest over a four-year period and bear exercise prices that are equal to the closing market price of the Company’s common stock on the NASDAQ Global Market on the respective grant dates.


		(c)	License Agreement with Former Officer

	Effective on February 24, 2012, the Company entered into a Drug Development Partnership and License Agreement for CU-906 and CU-908 with Guangzhou BeBetter Medicine Technology Company Ltd., or GBMT, a company organized under the laws of the People’s Republic of China. Dr. Changgeng Qian, the Company’s former Senior Vice President, Discovery and Preclinical Development, is the founder, owner, and legal representative of GBMT.

	Pursuant to the GMBT license agreement, the Company has granted to GBMT an exclusive royalty-free license, with the right to grant sublicenses subject to certain conditions, to develop, manufacture, market and sell any product containing CU-906 or CU-908 in China, Macau, Taiwan and Hong Kong, which is referred to as the GBMT territory. In addition, the Company has granted to GBMT a non-exclusive, royalty-free manufacturing license, with the right to grant sublicenses subject to certain conditions, to manufacture CU-906 or CU-908 or any product containing CU-906 or CU-908 outside of the GBMT Territory solely to import the compounds or products into the GBMT territory. GBMT has assumed all future development responsibility and will incur all future costs related to the development, registration and commercialization of products in the GBMT territory under the GMBT license agreement. Pursuant to the terms of the GMBT license agreement, the Company has retained rights, including the right to grant sublicenses, to develop, manufacture, market and sell any product containing CU-906 or CU-908 worldwide excluding the GBMT territory. The Company also has certain specified rights to any GBMT technology developed under the GMBT license agreement as well as certain specified rights to GBMT’s interest in joint technology developed under the GMBT license agreement. Furthermore, the Company has a right of first negotiation to obtain a license to CU-906 or CU-908 for the GBMT territory from GBMT.

	The Company provided GBMT with up to $400,000 in financial support for specified CU-908 pre-clinical activities related to enabling the filing by the Company of an IND with the FDA, provided that GBMT completes such CU-908 IND-enabling activities in accordance with specified criteria and delivers a U.S. IND package for CU-908 to the Company within prescribed timeframes as specified in the license agreement. All costs incurred under the license agreement will be expensed as incurred. During the years ended December 31, 2014 and 2012, the Company had incurred expenses of $266,667 and $133,333, respectively, under the GMBT license agreement reported within the research and development line item of the Company’s Consolidated Statements of Operations and Comprehensive Loss. No such expenses were incurred during the year ended December 31, 2013.

	Unless terminated earlier in accordance with its terms, the GMBT license agreement will expire on the later of (i) the expiration of the last-to-expire valid claim of the Company patents and the Company non-assert patents relating to the products, and (ii) such time as none of GBMT, its affiliates or sublicensees is commercializing any compound or product in the GBMT territory. Either party can terminate the GMBT license agreement with notice under prescribed circumstances, and the GMBT license agreement specifies the consequences to each party for such early termination.

Retirement_Savings_Plan

Retirement Savings Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Retirement Savings Plan	-12	RETIREMENT SAVINGS PLAN

	The Company has a 401(k) retirement savings plan covering substantially all of the Company’s employees. Matching Company cash contributions are at the discretion of the Board of Directors. For the years ended December 31, 2014, 2013 and 2012, the Board of Directors authorized matching contributions of $172,000, $145,000 and $153,000, respectively.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
Selected Quarterly Financial Data (Unaudited)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	-13	SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	The following are selected quarterly financial data for the years ended December 31, 2014 and 2013:


			Quarter Ended
			March 31,			June 30,			September 30,			December 31,
			2014			2014			2014			2014
	Revenues		$	1,284,633		$	4,801,285		$	1,764,864		$	1,992,699
	Loss from operations			(4,753,343	)		(1,544,787	)		(4,753,031	)		(4,811,088	)
	Net loss			(5,563,936	)		(1,895,785	)		(5,580,143	)		(5,688,870	)
	Net loss per common share (basic and diluted)		$	(0.06	)	$	(0.02	)	$	(0.06	)	$	(0.07	)
	Weighted average common shares (basic and diluted)			85,917,592			85,963,836			86,004,857			86,010,499


			Quarter Ended
			March 31,			June 30,			September 30,			December 31,
			2013			2013			2013			2013
	Revenues		$	871,435		$	5,404,377		$	7,202,083		$	1,524,137
	(Loss) income from operations			(4,357,364	)		(706,196	)		130,368			(4,483,217	)
	Net loss			(4,962,294	)		(1,293,848	)		(1,867,838	)		(4,198,032	)
	Net loss per common share (basic and diluted)		$	(0.06	)	$	(0.02	)	$	(0.02	)	$	(0.05	)
	Weighted average common shares (basic and diluted)			80,096,650			81,128,475			82,456,708			85,741,278

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	-14	SUBSEQUENT EVENTS
	Collaboration, License and Option Agreement with Aurigene Discovery Technologies, Ltd.
	In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies, Ltd., or Aurigene. The collaboration provides for inclusion of multiple programs, with the Company having the option to exclusively license compounds once a development candidate is nominated within each respective program. The partnership draws from each company’s respective areas of expertise, with Aurigene having the responsibility for conducting all discovery and preclinical activities, including IND-enabling studies and providing Phase 1 clinical trial supply, and the Company having responsibility for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia, for each program for which it exercises an option to obtain a license.
	The first two programs under the collaboration are an orally-available small molecule antagonist of programmed death ligand-1 (PD-L1) in the immuno-oncology field and an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field. The agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for the Company to extend the broad immuno-oncology exclusivity.
	In connection with the transaction, the Company issued to Aurigene approximately 17,120,131 shares of its common stock, or 19.9% of its outstanding common stock immediately prior to the transaction, in partial consideration for the rights granted to Curis under the collaboration agreement. The shares issued to Aurigene are subject to a lock-up agreement until January 18, 2017, with a portion of the shares being released from the lock-up in four equal bi-annual installments between now and that date.
	In addition, the Company has agreed to make payments to Aurigene as follows:

		•		for the first two programs: up to $52.5 million per program, including $42.5 million per program for approval and commercial milestones, plus specified approval milestone payments for additional indications, if any;

		•		for the third and fourth programs: up to $50 million per program, including $42.5 million per program for approval and commercial milestones, plus specified approval milestone payments for additional indications, if any; and

		•		for any program thereafter: up to $140.5 million per program, including $87.5 million per program in approval and commercial milestones, plus specified approval milestone payments for additional indications, if any.
	The Company has agreed to pay Aurigene royalties on any net sales ranging from high single digits to 10% in territories where it successfully commercializes products and will also share in amounts that it receives from sublicensees depending upon the stage of development of the respective molecule.

	Termination and Transition Agreement with Debiopharm
	On February 6, 2015, the Company entered into a termination and transition agreement with Debiopharm International S.A., or Debiopharm to terminate the August 5, 2009 license agreement between the Company and Debiopharm, under which the Company granted Debiopharm an exclusive, worldwide license to Debio 0932, a small molecule inhibitor of heat shock protein 90, or HSP90, as amended. The transition agreement is effective as of February 5, 2015.
	Under the terms of the termination and transition agreement, the licenses and all other rights granted by the Company related to Debio 0932 have been terminated and reverted to the Company effective as of the termination date. Debiopharm ceased enrollment in all clinical trials as of the termination date. In addition, the Company exercised its right, pursuant to the license agreement, to obtain a non-exclusive, worldwide, royalty-bearing license, with the right to sublicense, under intellectual property rights of Debiopharm to develop, make, have made, use, sell, offer for sale, have sold and import Debio 0932 and any product containing Debio 0932, and Debiopharm will transfer to the Company the U.S. investigational new drug application related to Debio 0932. Debiopharm also assigned its sole patent application related to Debio 0932 to the Company.
	Under the terms of the transition agreement, Debiopharm will transition ongoing Debio 0932 development and manufacturing activities to the Company and will transfer the manufacturing technology necessary for the manufacture of Debio 0932 and all data generated by or on behalf of Debiopharm relating to Debio 0932 to the Company.
	The Company has agreed to make the following payments to Debiopharm under the terms of the termination and transition agreement:
	Up-front drug product payment. The Company has agreed to pay $750,000 within fifteen (15) days of the termination date, primarily in consideration for Debiopharm providing Debio 0932 drug product for use in the Company’s future clinical studies.
	Milestone payments. The Company has agreed to make each of the following one-time payments to Debiopharm:

		(i)	$3,000,000 within 30 days after the first dosing of the first patient in the first Phase 3 clinical trial of Debio 0932; and

		(ii)	$10,000,000 within 30 days after receipt of the first marketing approval for Debio 0932 in the United States of America or any specified major European market (whichever occurs first);
	Royalties on the Company’s net sales. The Company has agreed to pay to Debiopharm royalties at a rate of 3% of net sales by the Company (excluding sales by the Company’s third party sublicensees) of products containing Debio 0932.
	Amounts that the Company receives from sublicensees. The Company has agreed to pay to Debiopharm the following percentages of amounts that the Company receives from third party sublicensees;

		(i)	10% of any royalties that the Company receives from third party sublicensees based on such sublicensees’ net sales of products containing Debio 0932; and

		(ii)	15% of any non-royalty sublicense payments that the Company receives from third party sublicensees, provided that the maximum aggregate amount payable by the Company to Debiopharm with respect to non-royalty sublicense payments is $20,000,000, unless such sublicense payments are attributable to the Company’s grant to a third party sublicensee of a license or sublicense to develop or commercialize a topical formulation of Debio 0932 for local, non-systemic delivery for the treatment of psoriasis, in which case there is no such maximum aggregate.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates		(a)	USE OF ESTIMATES
Use of Estimates	The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include revenue recognition, including estimates of the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the collectibility of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities, including our warrant liability. Actual results may differ from such estimates.
Consolidation		(b)	CONSOLIDATION
Consolidation	The accompanying consolidated financial statements include the Company and its wholly owned subsidiaries, Curis Royalty (see Note 7), Curis Securities Corporation, Inc. and Curis Pharmaceuticals (Shanghai) Co., Ltd., or Curis Shanghai. The Company has eliminated all intercompany transactions in each of the years ended December 31, 2014, 2013 and 2012.
Revenue Recognition		(c)	REVENUE RECOGNITION
	The Company’s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company’s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. The Company follows the provisions of the Financial Accounting Standards Board, or FASB, Codification Topic 605, Revenue Recognition.
	License Fees and Multiple Element Arrangements
	In January 2011, the Company adopted a new U.S. generally accepted accounting principles, or GAAP, accounting standard on a prospective basis which amends existing revenue recognition accounting guidance to provide accounting principles and application guidance on whether multiple deliverables exist, how the arrangement should be separated, and the consideration allocated. This new guidance eliminates the requirement to establish objective evidence of fair value of undelivered products and services and instead provides for separate revenue recognition based upon management’s best estimate of the selling price for an undelivered item when there is no vendor-specific objective evidence or third-party evidence to determine the fair value of the undelivered item.
	Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured and the Company has no further performance obligations under the license agreement. Multiple element arrangements, such as license and development arrangements are analyzed to determine whether the deliverables, which often include a license and performance obligations such as research and steering committee services, can be separated or whether they must be accounted for as a single unit of accounting in accordance with GAAP. The Company recognizes up-front license payments as revenue upon delivery of the license only if the license has stand-alone value. If the license is considered to not have stand-alone value, the arrangement would then be accounted for as a single unit of accounting and the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed.
	If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are determined to be performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.
	Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized. Revenue will be recognized using either a relative performance or straight-line method. The Company recognizes revenue using the relative performance method provided that the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and such performance obligations are provided on a best-efforts basis. Direct labor hours or full-time equivalents are typically used as the measure of performance. Revenue recognized under the relative performance method would be determined by multiplying the total payments under the contract, excluding royalties and payments contingent upon achievement of substantive milestones, by the ratio of level of effort incurred to date to estimated total level of effort required to complete the Company’s performance obligations under the arrangement. Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the relative performance method, as of each reporting period.
	If the Company cannot reasonably estimate the level of effort required to complete its performance obligations under an arrangement, the performance obligations are provided on a best-efforts basis and the Company can reasonably estimate when the performance obligation ceases or the remaining obligations become inconsequential and perfunctory, then the total payments under the arrangement, excluding royalties and payments contingent upon achievement of substantive milestones, would be recognized as revenue on a straight-line basis over the period the Company expects to complete its performance obligations. Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line basis, as of the period ending date.
	If the Company cannot reasonably estimate when its performance obligation either ceases or becomes inconsequential and perfunctory, then revenue is deferred until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.

	Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.
	Substantive Milestone Payments
	In April 2010, the FASB issued guidance on the milestone method for revenue recognition purposes. Previously, definitive guidance on when the use of the milestone method was appropriate did not exist. This guidance provides a framework of the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate.
	Collaboration agreements that contain substantive milestone payments are recognized upon achievement of the milestone only if:

		•		such milestone is commensurate with either of the following:

		a)	the Company’s performance to achieve the milestone (for example, the achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement); or

		b)	the enhancement of the value of the deliverable as a result of a specific outcome resulting from the Company’s performance to achieve the milestone (or substantive Company effort is involved in achieving the milestone);

		•		such milestone relates solely to past performance; and

		•		the amount of the milestone payment is reasonable relative to all deliverables and payment terms in the arrangement.
	Determination as to whether a payment meets the aforementioned conditions involves management’s judgment. If any of these conditions are not met, the resulting payment would not be considered a substantive milestone, and the resulting payment would be recognized as revenue as performance obligations are performed under either the relative performance or straight-line methods, as applicable, and in accordance with these policies as described above. In addition, the determination that one such payment was not a substantive milestone could prevent the Company from concluding that subsequent milestone payments were substantive milestones and, as a result, any additional milestone payments could also be considered part of the consideration for the single unit of accounting and would be recognized as revenue as such performance obligations are performed under either the relative performance or straight-line methods, as applicable. Milestones that are tied to regulatory approval are not considered probable of being achieved until such approval is received. Milestones tied to counter-party performance are not included in the Company’s revenue model until the performance conditions are met.
	Reimbursement of Costs
	Reimbursement of research and development costs by third party collaborators is recognized as revenue provided the Company has determined that it is acting primarily as a principal in the transaction according to the provisions outlined in the FASB Codification Topic 605-45, Revenue Recognition, Principal Agent Considerations, the amounts are determinable and collection of the related receivable is reasonably assured.
	Royalty Revenue
	Since the first quarter of 2012, the Company has recognized royalty revenues related to Genentech’s and Roche’s sales of Erivedge. Royalty revenue is recognized upon the sale of the related products based on contractual terms, provided that the royalty amounts are fixed or determinable, collection of the related receivable is reasonably assured and we have no remaining performance obligations under the arrangement. If royalties are received when the Company was remaining performance obligations, it expects to attribute the royalty payments to the services being provided under the arrangement and therefore to recognize such royalty payments as such performance obligations are performed under either the relative performance or straight line methods, as applicable, and in accordance with these policies as described above. The Company expects to recognize royalty revenue in future quarters from Genentech’s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Notes 3(a) and 7). However, Erivedge royalties will service Curis Royalty’s debt to BioPharma-II, and only amounts in excess of certain quarterly repayment caps, if any, will be available to the Company for use in operations.
	Deferred Revenue
	Amounts received prior to satisfying the above revenue recognition criteria are recorded as short term deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized during the year ending December 31, 2015 would be classified as long-term deferred revenue. As of December 31, 2014 and 2013, the Company had no amounts classified as short-term or long-term deferred revenue.
	Summary
	During the years ended December 31, 2014, 2013 and 2012, total gross revenues from the Company’s collaborators as a percent of total gross revenues of the Company were as follows:


			Year Ended December 31,
			2014			2013			2012
	Genentech			100	%		95	%		94	%
	LLS			—	%		4	%		6	%

Research and Development		(d)	RESEARCH AND DEVELOPMENT
	Research and development expense consists of costs incurred to discover, research and develop drug candidates. These expenses consist primarily of: (1) salaries and related expenses for personnel including stock-based compensation expense; (2) outside service costs, including clinical research organizations and medicinal chemistry; (3) sublicense payments; and (4) the costs of supplies and reagents, consulting, and occupancy and depreciation charges. In addition, the Company incurred in-process research and development expenses of $9,500,000 during the year ended December 31, 2012, representing the one-time license and technology transfer fee related to the license of CUDC-427 from Genentech (see Note 3(b)). The Company expenses research and development costs as incurred.

	The Company recognizes cost of royalties on Erivedge royalty revenue earned under the June 2003 collaboration with Genentech related to obligations to third-party university licensors. The Company is also incurring research and development expenses under this collaboration related to the maintenance of these third-party licenses to certain background technologies. In addition, the Company records research and development expense for obligations to certain third-party university licensors upon earning payments from Genentech related to the achievement of clinical development and regulatory objectives under this collaboration.
Cash Equivalents and Investments
		(e)	CASH EQUIVALENTS AND INVESTMENTS
	Cash equivalents consist of short-term, highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. The Company’s short-term investments are marketable securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable securities with original maturities of greater than twelve months from the balance sheet. Marketable securities consist of commercial paper, corporate bonds and notes, and government obligations. All of the Company’s investments have been designated as available-for-sale and are stated at fair value with any unrealized holding gains or losses included as a component of stockholders’ equity and any realized gains and losses recorded in the statement of operations in the period the securities are sold.
	Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Realized gains and losses, dividends and interest income are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
	The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2014 are as follows:


			Amortized			Unrealized			Unrealized			Fair Value
			Cost			Gain			Loss			Fair Value
	Corporate bonds and notes—short-term		$	42,011,286		$	4,883		$	(13,387	)	$	42,002,782
	Corporate bonds and notes—long-term			791,261			—			(2,493	)		788,768

	Total investments		$	42,802,547		$	4,883		$	(15,880	)	$	42,791,550

	Short-term investments have maturities ranging from one and twelve months with a weighted average maturity of 4.1 months. Long-term investments have maturities ranging from January 2016 to May 2016 with a weighted average maturity of 13.8 months.
	The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of December 31, 2013 with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows:


			Amortized			Unrealized			Unrealized			Fair Value
			Cost			Gain			Loss			Fair Value
	Corporate bonds and notes		$	47,091,593		$	9,036		$	(15,476	)	$	47,085,153
	US government and municipal obligations			501,170			10			—		$	501,180

	Total investments		$	47,592,763		$	9,046		$	(15,476	)	$	47,586,333

	In addition, a certificate of deposit in the amount of $1,001,802 that the Company held as of December 31, 2013 was included within short-term investments in the consolidated balance sheet but is excluded from the table above as it was not deemed to be a security.
	As of December 31, 2013, the Company also recorded long-term investments of $10,726,685 on its Consolidated Balance Sheet. This amount is comprised of corporate and government-secured debt securities with maturities ranging from January 2015 to May 2015 with a weighted average maturity of 14.3 months and with amortized cost totaling $10,727,958, less unrealized net losses of $1,273.
Fair Value of Financial Instruments	(f)	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP also defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact.

	The FASB Codification Topic 820, Fair Value Measurements and Disclosures, requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:


	Level 1		Quoted prices in active markets for identical assets or liabilities.

	Level 2		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s warrant liability was valued using a probability-weighted Black-Scholes model, discussed further in Note 9, and is therefore classified as Level 3.
	In accordance with the fair value hierarchy, the following table shows the fair value as of December 31, 2014 and 2013 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at December 31, 2014 and 2013.


			Quoted Prices in			Other			Unobservable			Fair Value
			Active Markets			Observable			Inputs
			(Level 1)			Inputs			(Level 3)
						(Level 2)
	As of December 31, 2014:
	Cash equivalents
	Money market funds		$	4,419,894		$	—		$	—		$	4,419,894
	Municipal bonds			—			1,090,000			—			1,090,000
	Short- and long-term investments
	Corporate commercial paper, stock, bonds and notes			40,091,800			2,699,750			—			42,791,550

	Total assets at fair value		$	44,511,694		$	3,789,750		$	—		$	48,301,444



			Quoted Prices in			Other			Unobservable			Fair Value
			Active Markets			Observable			Inputs
			(Level 1)			Inputs			(Level 3)
						(Level 2)
	As of December 31, 2013:
	Cash equivalents
	Money market funds		$	5,535,716		$	—		$	—		$	5,535,716
	Corporate commercial paper, bonds and notes			—			1,749,983			—			1,749,983
	Municipal bonds			—			1,110,000			—			1,110,000
	Short- and long-term investments
	US government obligations			—			1,151,932			—			1,151,932
	Corporate commercial paper, stock, bonds and notes			20,176,154			36,984,932			—			57,161,086

	Total assets at fair value		$	25,711,870		$	40,996,847		$	—		$	66,708,717

	Warrant liability			—			—			716,786			716,786

	Total liabilities at fair value		$	—		$	—		$	716,786		$	716,786

	The above table excludes a certificate of deposit in the amount of $1,001,802 that the Company held as of December 31, 2013.
	The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the years ended December 31, 2014 and 2013:


	Balance at December 31, 2012		$	1,488,179
	Change in fair value			(771,393	)

	Balance at December 31, 2013		$	716,786
	Change in fair value			(716,786	)

	Balance at December 31, 2014		$	—

	The remaining 1,373,517 warrants outstanding as of December 31, 2014 expired unexercised in January 2015.

Long-Lived Assets Other than Goodwill		(g)	LONG-LIVED ASSETS OTHER THAN GOODWILL
	Long-lived assets other than goodwill consist of property and equipment. The aggregate net balances for these long-lived assets were $407,738 and $445,655 as of December 31, 2014 and 2013, respectively. The Company applies the guidance in FASB Codification Topic 360-10-05, Impairment or Disposal of Long-Lived Assets. If it were determined that the carrying value of the Company’s other long-lived assets might not be recoverable based upon the existence of one or more indicators of impairment, the Company would measure an impairment based on the difference between the carrying value and fair value of the asset. The Company did not recognize any impairment charges for the years ended December 31, 2014, 2013 or 2012.
	Purchased equipment is recorded at cost. The Company does not currently hold any leased equipment. Depreciation and amortization are provided on the straight-line method over the estimated useful lives of the related assets or the remaining terms of the leases, whichever is shorter, as follows:


	Asset Classification		Estimated Useful Life
	Laboratory equipment, computers and software		3-5 years
	Leasehold improvements		Lesser of life of the lease or the life of the asset
	Office furniture and equipment		5 years
	The Company incurred debt issuance costs totaling $421,715 in connection with the Curis Royalty loan transaction, of which $215,000 related to expenses that the Company paid to third parties on behalf of BioPharma-II and the remaining $206,715 were incurred directly by the Company. The debt issuance costs incurred directly by the Company were capitalized as assets and will be amortized over the estimated term of the debt using the straight-line. Assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires management to make estimates that could impact the Company’s short- and long-term classification of the debt issuance costs, as well as the period over which these costs will be amortized (see Note 7). As of December 31, 2014 and 2013, the Company had recorded short-term debt issuance costs of $43,616 and $51,441, respectively, and long-term debt issuance costs of $64,564 and $101,055, respectively. These costs are reported within the prepaid expenses and other current assets and other assets line items, respectively, in the Company’s Consolidated Balance Sheet at December 31, 2014 and 2013.
Goodwill		(h)	GOODWILL
Goodwill	As of December 31, 2014 and 2013, the Company had recorded goodwill of $8,982,000. The Company applies the guidance in the FASB Codification Topic 350, Intangibles – Goodwill and Other. During each of December 2014, 2013 and 2012, the Company completed its annual goodwill impairment tests and determined that the Company represented a single reporting unit and as of those dates the fair value of the Company exceeded the carrying value of its net assets. Accordingly, no goodwill impairment was recognized for the years ended December 31, 2014, 2013 and 2012.
Treasury Stock	(i)	TREASURY STOCK
	On May 31, 2002, the Company announced that its Board of Directors had approved the repurchase of up to $3,000,000 of the Company’s common stock. The Company accounted for its common stock repurchases as treasury stock under the cost method. In 2002, the Company repurchased 1,047,707 shares of its common stock at a cost of $891,274 pursuant to this repurchase program.
	The Company’s 2000 Stock Incentive Plan and the Amended and Restated 2010 Plan generally allow participants to purchase common stock upon the exercise of a stock option by delivery of shares of Company common stock held directly by the participant, with such shares of common stock valued at the closing price on the Nasdaq Global Market, or NASDAQ, on the date of exercise. During the year ended December 31, 2013, certain executive officers and a director exercised stock options by remitting shares of Curis common stock then held by the respective person. The Company accounted for the value of the common stock remitted to the Company in satisfaction of the exercise price as treasury stock under the cost method. These option holders remitted an aggregate of 175,139 shares during the year ended December 31, 2013 with an aggregate value equal to $632,755. As of December 31, 2014, the Company had repurchased an aggregate of 1,222,846 shares of its common stock at a total cost of $1,524,029.
Basic and Diluted Loss Per Common Share		(j)	BASIC AND DILUTED LOSS PER COMMON SHARE
	Basic and diluted net losses per share were determined by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, as the effect of the potential common stock equivalents is antidilutive due to the Company’s net loss position for all periods presented. Antidilutive securities consist of stock options and warrants outstanding as of the respective reporting period. Antidilutive securities as of December 31, 2014, 2013 and 2012 consisted of the following:


			For the Years Ended December 31,
			2014			2013			2012
	Stock options outstanding			11,319,619			10,077,805			10,437,761
	Warrants outstanding			1,373,517			1,373,517			1,373,517

	Total antidilutive securities			12,693,136			11,451,322			11,811,278
Stock-Based Compensation		(k)	STOCK-BASED COMPENSATION
Stock-Based Compensation	The Company adopted Statement of Financial Accounting Standards, or SFAS, No. 123 (revised 2004), Share-Based Payment (SFAS 123(R)), which established standards for the accounting of transactions in which an entity exchanges its equity instruments for goods or services, and is now referred to as the FASB Codification Topic 718, Compensation—Stock Compensation. Topic 718 focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. Topic 718 requires that the fair value of such equity instruments be recognized as an expense in the financial statements as services are performed
Operating Leases		(l)	OPERATING LEASES
Operating Leases	The Company currently has one facility located at 4 Maguire Road in Lexington, Massachusetts under a noncancellable operating lease agreement for office and laboratory space. The rent payments for this facility escalate over the lease term and the Company expenses its obligations under this lease agreement on a straight-line basis over the term of the lease (see Note 8(a)).
Concentration of Risk		(m)	CONCENTRATION OF RISK
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, short- and long-term investments. The Company invests directly in commercial paper of financial institutions and corporations with A-/Aa3 or better long-term ratings and A-1/P-1 short term debt ratings and U.S. Treasury securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s credit risk related to investments is reduced as a result of the Company’s policy to limit the amount invested in any one issue.
	The Company’s accounts receivable at December 31, 2014, represents amounts due from collaborators, primarily for royalties earned on sales of Erivedge by Genentech and Roche.
	The Company relies on third parties to supply certain raw materials necessary to produce its drug candidates, including CUDC-907 and CUDC-427, for preclinical studies and clinical trials. There are a small number of suppliers for certain raw materials that the Company uses to manufacture its drug candidates.
Comprehensive Loss		(n)	COMPREHENSIVE LOSS
Comprehensive Loss	Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes unrealized holding gains and losses arising during the period on available-for-sale securities that are not other-than-temporarily impaired.
New Accounting Pronouncements		(o)	NEW ACCOUNTING PRONOUNCEMENTS
	In May 2014, the FASB issued guidance codified in ASC 606, Revenue Recognition—Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition, and is effective for public companies for fiscal years beginning after December 15, 2016. The Company is currently evaluating the impact of the provisions of ASC 606.
	In August 2014, the FASB issued an accounting standards update, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which is included in ASC 205, Presentation of Financial Statements. This update provides an explicit requirement for management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The guidance will be effective for fiscal years beginning after December 15, 2016, and applied prospectively; early adoption is also permitted. The Company does not expect adoption of this guidance to have a material impact on its financial condition or results of operations.
Segment Reporting		(p)	SEGMENT REPORTING
Segment Reporting	The Company is engaged solely in the discovery and development of innovative drug candidates for the treatment of human cancers. Accordingly, the Company has determined that it operates in one operating segment.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Revenues from Collaborators as a Percent of Total Gross Revenues	During the years ended December 31, 2014, 2013 and 2012, total gross revenues from the Company’s collaborators as a percent of total gross revenues of the Company were as follows:


		Year Ended December 31,
		2014			2013			2012
	Genentech		100	%		95	%		94	%
	LLS		—	%		4	%		6	%

Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments	The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2014 are as follows:


		Amortized			Unrealized			Unrealized			Fair Value
		Cost			Gain			Loss			Fair Value
	Corporate bonds and notes—short-term	$	42,011,286		$	4,883		$	(13,387	)	$	42,002,782
	Corporate bonds and notes—long-term		791,261			—			(2,493	)		788,768

	Total investments	$	42,802,547		$	4,883		$	(15,880	)	$	42,791,550

	The amortized cost, unrealized losses and fair value of short-term investments available-for-sale as of December 31, 2013 with maturity dates ranging between one and twelve months and with a weighted average maturity of 4.7 months are as follows:


		Amortized			Unrealized			Unrealized			Fair Value
		Cost			Gain			Loss			Fair Value
	Corporate bonds and notes	$	47,091,593		$	9,036		$	(15,476	)	$	47,085,153
	US government and municipal obligations		501,170			10			—		$	501,180

	Total investments	$	47,592,763		$	9,046		$	(15,476	)	$	47,586,333

Financial Assets or Liabilities Measured at Fair Value on Recurring Basis	In accordance with the fair value hierarchy, the following table shows the fair value as of December 31, 2014 and 2013 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at December 31, 2014 and 2013.


		Quoted Prices in			Other			Unobservable			Fair Value
		Active Markets			Observable			Inputs
		(Level 1)			Inputs			(Level 3)
					(Level 2)
	As of December 31, 2014:
	Cash equivalents
	Money market funds	$	4,419,894		$	—		$	—		$	4,419,894
	Municipal bonds		—			1,090,000			—			1,090,000
	Short- and long-term investments
	Corporate commercial paper, stock, bonds and notes		40,091,800			2,699,750			—			42,791,550

	Total assets at fair value	$	44,511,694		$	3,789,750		$	—		$	48,301,444



		Quoted Prices in			Other			Unobservable			Fair Value
		Active Markets			Observable			Inputs
		(Level 1)			Inputs			(Level 3)
					(Level 2)
	As of December 31, 2013:
	Cash equivalents
	Money market funds	$	5,535,716		$	—		$	—		$	5,535,716
	Corporate commercial paper, bonds and notes		—			1,749,983			—			1,749,983
	Municipal bonds		—			1,110,000			—			1,110,000
	Short- and long-term investments
	US government obligations		—			1,151,932			—			1,151,932
	Corporate commercial paper, stock, bonds and notes		20,176,154			36,984,932			—			57,161,086

	Total assets at fair value	$	25,711,870		$	40,996,847		$	—		$	66,708,717

	Warrant liability		—			—			716,786			716,786

	Total liabilities at fair value	$	—		$	—		$	716,786		$	716,786
Fair Value of Warrant Liability	The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the years ended December 31, 2014 and 2013:


	Balance at December 31, 2012	$	1,488,179
	Change in fair value		(771,393	)

	Balance at December 31, 2013	$	716,786
	Change in fair value		(716,786	)

	Balance at December 31, 2014	$	—
Summary of Estimated Useful Lives of Long Lived Assets Other Than Goodwill	The Company does not currently hold any leased equipment. Depreciation and amortization are provided on the straight-line method over the estimated useful lives of the related assets or the remaining terms of the leases, whichever is shorter, as follows:



	Asset Classification	Estimated Useful Life
	Laboratory equipment, computers and software	3-5 years
	Leasehold improvements	Lesser of life of the lease or the life of the asset
	Office furniture and equipment	5 years

Summary of Antidilutive Securities - Stock Options and Warrants	Antidilutive securities as of December 31, 2014, 2013 and 2012 consisted of the following:


		For the Years Ended December 31,
		2014			2013			2012
	Stock options outstanding		11,319,619			10,077,805			10,437,761
	Warrants outstanding		1,373,517			1,373,517			1,373,517

	Total antidilutive securities		12,693,136			11,451,322			11,811,278

Stock_Plans_and_Stock_Based_Co1

Stock Plans and Stock Based Compensation (Tables)	12 Months Ended
Stock Plans and Stock Based Compensation (Tables)	Dec. 31, 2014
Valuation Assumptions Used to Calculate Fair Value of Employee Options Awarded	In determining the fair value of stock options, the Company uses the Black-Scholes option pricing model. The Black-Scholes option pricing model contained the following weighted average assumptions for employee option grants issued in each of the following years:


		For the Year Ended
		December 31,
		2014			2013			2012
	Expected term (years)—Employees		6			6			6
	Expected term (years)—Officers and Directors		7			7			6
	Risk-free interest rate		1.9	%		1.0-2.1	%		1.0-1.2	%
	Expected volatility		70-71	%		70-72	%		74-76	%
	Expected dividend yield		None			None			None
Summary of Stock Option Activity	A summary of stock option activity under the Amended and Restated 2010 Plan, the 2000 Stock Incentive Plan and the 2000 Director Stock Option Plan is summarized as follows:


		Number of			Weighted
		Shares			Average
					Exercise
					Price per
					Share
	Outstanding, December 31, 2013 (6,884,869 exercisable at weighted average price of $2.44 per share)		10,077,805		$	2.79
	Granted		2,275,500			2.65
	Exercised		(114,812	)		1.86
	Cancelled		(918,874	)		4.11

	Outstanding, December 31, 2014 (7,534,372 exercisable at weighted average price of $2.45 per share)		11,319,619		$	2.66

	Vested and unvested expected to vest		10,980,633		$	2.66

Summary of Compensation Expense Related to ESPP	For the years ended December 31, 2014, 2013 and 2012, the Company recorded compensation expense related to its ESPP and calculated the fair value of shares expected to be purchased under the ESPP using the Black-Scholes models with the following assumptions:


		For the Year Ended December 31,
		2014			2013			2012
	Compensation expense recognized under ESPP	$	25,604		$	40,008		$	72,833
	Expected term		6 months			6 months			6 months
	Risk-free interest rate		0.06-0.09	%		0.08-0.1	%		0.05-0.15	%
	Volatility		55-66	%		42-66	%		42-75	%
	Dividends		None			None			None
Employee and Non Employee Share Based Compensation Expense Allocation	For the years ended December 31, 2014, 2013 and 2012, the Company recorded employee and non-employee stock-based compensation expense to the following line items in its Costs and Expenses section of the Consolidated Statements of Operations and Comprehensive Loss:


		For the Year Ended December 31,
		2014			2013			2012
	Research and development expenses	$	671,063		$	879,052		$	1,075,134
	General and administrative expenses		2,388,926			2,123,189			2,548,777

	Total stock-based compensation expense	$	3,059,989		$	3,002,241		$	3,623,911
Vesting Tied to Market Conditions [Member]
Valuation Assumptions Used to Calculate Fair Value of Employee Options Awarded	The key assumptions used in these Monte Carlo simulation models and resulting valuations are noted in the following table:



		Market		Market
		Condition		Condition
		Options		Options
		Granted		Granted
		February 18,		June 2,
		2014		2014
	Expected life (years)—officers	6		6
	Risk-free interest rate	1.90%		2.10%
	Volatility	70%		65%
	Dividends	None		None
	Number of options granted	640,000		400,000
	Fair value per share	$1.20		$0.34

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following:


		December 31,
		2014			2013
	Laboratory equipment, computers and software	$	1,963,017		$	1,941,588
	Leasehold improvements		62,621			62,621
	Office furniture and equipment		311,664			354,875

			2,337,302			2,359,084
	Less—Accumulated depreciation and amortization		(1,929,564	)		(1,913,429	)

	Total	$	407,738		$	445,655

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
Accrued Liabilities (Tables)	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Accrued Liabilities	Accrued liabilities consist of the following:


		December 31,
		2014		2013
	Accrued compensation	$	1,386,226	$	1,267,954
	Professional fees		122,850		166,200
	Accrued interest on debt (see Note 7)		286,075		298,935
	Other		212,548		178,390

	Total	$	2,007,699	$	1,911,479

Debt_Tables

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt Issuance Costs	The debt issuance costs incurred directly by the Company were capitalized as assets and those costs paid on behalf of BioPharma-II have been netted against the debt and accrued interest in the Company’s Condensed Consolidated Balance Sheets as of December 31, 2014 and 2013 as detailed in the following table:


		As of
		December 31,
		2014			2013
	Other current assets	$	43,616		$	51,441
	Other assets		64,564			101,055

	Total debt issuance costs		108,180			152,496

	Debt, current		5,748,059			2,663,677
	Debt issue costs, current		(38,074	)		(53,503	)

	Debt, current portion net of issuance costs	$	5,709,985		$	2,610,174


	Debt, long-term		22,664,787			28,050,291
	Debt issue costs, long-term		(75,729	)		(105,105	)

	Debt, net of current portion and issuance costs	$	22,589,058		$	27,945,186
Schedule of Future Payments of Principal on Loan	At December 31, 2014, the Company estimates that its future payments of principal on the loan are as follows:


		Principal
	2015	$	5,748,059
	2016		10,011,236
	2017		12,653,551
	Thereafter		—

	Total payments		28,412,846

	Less current portion, gross		(5,748,059	)

	Total long-term debt obligations, gross	$	22,664,787

Commitments_Tables

Commitments (Tables)	12 Months Ended
Commitments (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Lease Commitments	The Company’s remaining operating lease commitments for all leased facilities with an initial or remaining term of at least one year are as follows:


	Year Ending December 31,
	2015	$	651,000
	2016		676,000
	2017		700,000
	2018		59,000

	Total minimum payments	$	2,086,000

Common_Stock_and_Warrant_Liabi1

Common Stock and Warrant Liability (Tables)	12 Months Ended
Common Stock and Warrant Liability (Tables)	Dec. 31, 2014
Text Block [Abstract]
Estimated Fair Value of Warrants	The Company has estimated the fair value of the warrants using a Black-Scholes option pricing model under various probability-weighted outcomes which take into consideration the protective, but limited, cash-settlement feature of the warrants, with updated assumptions at each reporting date as detailed in the following table:



		As of December 31,
		2014			2013			2012
	Fair value of the warrants	$	—		$	716,786		$	1,488,179
	Expected term		0.1 years			1.1 years			2.1 years
	Risk-free interest rate		0	%		0.16	%		0.27	%
	Volatility		82	%		65	%		58	%
	Dividends		None			None			None

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation	The provision for income taxes for continuing operations was at rates different from the U.S. federal statutory income tax rate for the following reasons:

		For the Year Ended
		December 31,
		2014			2013			2012
	Statutory federal income tax rate		34	%		34	%		34	%
	State income taxes, net of federal benefit		4.9	%		5.2	%		5.8	%
	Research and development tax credits		3.2	%		8.5	%		0.8	%
	Deferred compensation		(1.6	%)		0.8	%		2.1	%
	Interest expense		(1.6	%)		(2.5	%)		—	%
	Fair value of warrants		1.3	%		2.1	%		—	%
	NOL expirations		(2.8	%)		(5.2	%)		(36.0	%)
	Other		0.1	%		0.1	%		(1.7	%)
	Net decrease in valuation allowance		(37.5	%)		(43.0	%)		(5.0	%)

	Effective income tax rate		—	%		—	%		—	%

Components of Deferred Tax Assets	The principle components of the Company’s deferred tax assets at December 31, 2014 and 2013, respectively, are as follows:

		December 31,
		2014			2013
	Deferred Tax Assets:
	Net operating loss carryforwards	$	78,289,000		$	72,446,000
	Research and development tax credit carryforwards		12,212,000			11,588,000
	Depreciation and amortization		3,591,000			3,891,000
	Capitalized research and development expenditures		24,059,000			23,711,000
	Impairment of investments		120,000			120,000
	Stock options		3,534,000			2,723,000
	Accrued expenses and other		114,000			118,000
	Deferred interest expense		—			307,000

	Total Gross Deferred Tax Asset		121,919,000			114,904,000
	Valuation Allowance		(121,919,000	)		(114,904,000	)

	Net Deferred Tax Asset	$	—		$	—

Classification of Deferred Tax Asset	The classification of the above deferred tax assets is as follows:

		December 31,
		2014			2013
	Deferred Tax Assets:
	Current deferred tax assets	$	39,000		$	35,000
	Non-current deferred tax assets		121,880,000			114,869,000
	Valuation Allowance		(121,919,000	)		(114,904,000	)

	Net Deferred Tax Asset	$	—		$	—

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
Selected Quarterly Financial Data (Unaudited) (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Data	The following are selected quarterly financial data for the years ended December 31, 2014 and 2013:


		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2014			2014			2014			2014
	Revenues	$	1,284,633		$	4,801,285		$	1,764,864		$	1,992,699
	Loss from operations		(4,753,343	)		(1,544,787	)		(4,753,031	)		(4,811,088	)
	Net loss		(5,563,936	)		(1,895,785	)		(5,580,143	)		(5,688,870	)
	Net loss per common share (basic and diluted)	$	(0.06	)	$	(0.02	)	$	(0.06	)	$	(0.07	)
	Weighted average common shares (basic and diluted)		85,917,592			85,963,836			86,004,857			86,010,499


		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Revenues	$	871,435		$	5,404,377		$	7,202,083		$	1,524,137
	(Loss) income from operations		(4,357,364	)		(706,196	)		130,368			(4,483,217	)
	Net loss		(4,962,294	)		(1,293,848	)		(1,867,838	)		(4,198,032	)
	Net loss per common share (basic and diluted)	$	(0.06	)	$	(0.02	)	$	(0.02	)	$	(0.05	)
	Weighted average common shares (basic and diluted)		80,096,650			81,128,475			82,456,708			85,741,278

Operations_Additional_Informat

Operations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Segment
Nature Of Business [Abstract]
Reportable segments	1

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2002	31-May-02
	CreditFacility
	Segment
Significant Accounting Policies [Line Items]
Amounts classified as short-term deferred revenue	$0	$0
Amounts classified as long-term deferred revenue	0	0
In-process research and development			9,500,000
Available for sale securities weighted average maturity		4 months 21 days
Long-term investments	788,768	10,726,685
Amortized Cost	42,802,547	47,592,763
Assets measured at fair value on a nonrecurring basis	0	0
Liabilities measured at fair value on a nonrecurring basis	0	0
Certificate of deposit held by company		1,001,802
Remaining warrant outstanding	1,373,517
Warrant expiration date	2015-01
Long-lived assets	407,738	445,655
Impairment charges	0	0	0
Debt issuance costs gross	108,180	152,496	421,715
Debt issue costs, current	43,616	51,441
Debt issue costs, long-term	64,564	101,055
Goodwill	8,982,000	8,982,000
Goodwill impairment charges	0	0	0
Approved repurchase of common stock					3,000,000
Common stock surrendered to pay the exercise price				1,047,707
Repurchase shares of common stock, value		632,755		891,274
Option cost	1,524,029	1,524,029
Facility under noncancellable operating lease agreement	1
Number of operating segment	1
Certificates of Deposit [Member]
Significant Accounting Policies [Line Items]
Certificate of deposit		1,001,802
Curis Royalty [Member]
Significant Accounting Policies [Line Items]
Debt issuance costs gross			206,715
BioPharma-II [Member]
Significant Accounting Policies [Line Items]
Debt issuance costs gross			215,000
Corporate and Government-Secured Debt Securities [Member]
Significant Accounting Policies [Line Items]
Available for sale securities weighted average maturity		14 months 9 days
Investment maturity period range start		2015-01
Investment maturity period range end		2015-05
Amortized Cost		10,727,958
Unrealized net losses		1,273
Amended and Restated 2010 Plan [Member]
Significant Accounting Policies [Line Items]
Common stock surrendered to pay the exercise price	1,222,846	175,139
Option cost	1,524,029	632,755
Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities weighted average maturity	4 months 3 days
Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities weighted average maturity	13 years 9 months 18 days
Minimum [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range		1 month
Minimum [Member] \| Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range	1 month
Minimum [Member] \| Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range	2016-01
Maximum [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range		12 months
Maximum [Member] \| Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range	12 months
Maximum [Member] \| Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range	2016-05
Genentech IAP License [Member]
Significant Accounting Policies [Line Items]
In-process research and development			$9,500,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Revenues from Collaborators as a Percent of Total Gross Revenues (Detail) (Revenue, Rights Granted [Member], Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Genentech Inc [Member]
Revenue, Major Customer [Line Items]
Total gross revenue	100.00%	95.00%	94.00%
LLS [Member]
Revenue, Major Customer [Line Items]
Total gross revenue		4.00%	6.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$42,802,547	$47,592,763
Unrealized Gain	4,883	9,046
Unrealized Loss	-15,880	-15,476
Fair Value	42,791,550	47,586,333
Corporate Bonds and Notes [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		47,091,593
Unrealized Gain		9,036
Unrealized Loss		-15,476
Fair Value		47,085,153
Corporate Bonds and Notes [Member] \| Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	42,011,286
Unrealized Gain	4,883
Unrealized Loss	-13,387
Fair Value	42,002,782
Corporate Bonds and Notes [Member] \| Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	791,261
Unrealized Loss	-2,493
Fair Value	788,768
US Government and Municipal Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		501,170
Unrealized Gain		10
Fair Value		$501,180

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Financial Assets or Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$716,786	$1,488,179
Fair Value Measurements Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	66,708,717		48,301,444
Warrant liability	716,786
Total liabilities at fair value	716,786
Fair Value Measurements Recurring [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	5,535,716		4,419,894
Corporate commercial paper, bonds and notes	1,749,983
Municipal bonds	1,110,000		1,090,000
Fair Value Measurements Recurring [Member] \| Short-and Long-term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US government obligations	1,151,932
Corporate commercial paper, bonds and notes	57,161,086		42,791,550
Fair Value Measurements Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	25,711,870		44,511,694
Fair Value Measurements Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	5,535,716		4,419,894
Fair Value Measurements Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member] \| Short-and Long-term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate commercial paper, bonds and notes	20,176,154		40,091,800
Fair Value Measurements Recurring [Member] \| Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	40,996,847		3,789,750
Fair Value Measurements Recurring [Member] \| Other Observable Inputs (Level 2) [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate commercial paper, bonds and notes	1,749,983
Municipal bonds	1,110,000		1,090,000
Fair Value Measurements Recurring [Member] \| Other Observable Inputs (Level 2) [Member] \| Short-and Long-term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US government obligations	1,151,932
Corporate commercial paper, bonds and notes	36,984,932		2,699,750
Fair Value Measurements Recurring [Member] \| Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	716,786
Total liabilities at fair value	$716,786

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Fair Value of Warrant Liability (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Balance Beginning	$716,786	$1,488,179
Change in fair value	-716,786	-771,393
Balance Ending		$716,786

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Long Lived Assets Other Than Goodwill (Detail)	12 Months Ended
	Dec. 31, 2014
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	Lesser of life of the lease or the life of the asset
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member] \| Laboratory Equipment, Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Maximum [Member] \| Laboratory Equipment, Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Summary of Antidilutive Securities - Stock Options and Warrants (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total antidilutive securities	12,693,136	11,451,322	11,811,278
Stock Options Outstanding [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total antidilutive securities	11,319,619	10,077,805	10,437,761
Warrants Outstanding [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total antidilutive securities	1,373,517	1,373,517	1,373,517

Research_and_Development_Colla1

Research and Development Collaborations - Additional Information (Detail) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2012	Nov. 30, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License fees	$3,000,000	$10,000,000	$14,000,000
Research and development	13,659,398	12,926,834	15,492,302
Fair value of one-time issuance of common stock			964,000
Percentage research and development expenses	5.00%	5.00%
Recognized royalty revenue	6,757,023	3,942,136	1,529,644
One time cash payment to university licensor	339,578	197,796	176,482
Research and development revenue	86,458	1,059,896	1,442,347
Accounts receivable from Genentech	1,960,995	1,477,188
In-process research and development			9,500,000
Royalty Obligation on successful progresses of CUDC - 907 through clinical trials	4,125,000
Multiplier applied to milestone payments received to determine royalty obligation	250.00%
Follow up Diligence Period under Development	5 years
Roche [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent payments received			4,000,000
Genentech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligibility to receive contingent cash payments under the collaboration	115,000,000
Amount received for specified clinical development and regulatory objectives	59,000,000
Percentage of royalty rate decrease	2.00%
Expiry date of agreement	6 months
Activities occurred under the agreement	12 months
License fees	3,000,000	10,000,000	14,000,000
Contingent cash receipt related to licensing agreement	4,364,000
Research and development	225,707		2,114,000
Number of common stock shares issued to university licensors				200,000
Number of university licensors in connection with the FDA-approval of Erivedge			2
Recognized royalty revenue	6,757,023	3,942,136	1,529,644
One time cash payment to university licensor	339,578	197,796	176,482
Percentage of royalties earned			5.00%
Research and development revenue	265,047	291,448	363,000
Accounts receivable from Genentech	1,958,000	1,455,000
Genentech Inc [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of royalty on net sales	7.50%
Royalty portion of annual worldwide net sales	600,000,000
Percentage of royalty	5.50%
Genentech Inc [Member] \| Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of royalty on net sales	5.00%
Royalty portion of annual worldwide net sales	150,000,000
Percentage of royalty	3.00%
Genentech Inc [Member] \| University Licensors [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of one-time issuance of common stock			964,000
One time cash payment to university licensor			100,000
Genentech IAP License [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
In-process research and development			9,500,000
Royalty payment period	10 years
Notice period for termination of license	90 days
Leukemia and Lymphoma Society [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Earned milestone payment		650,000	1,000,000		1,650,000
Royalty Obligation on successful progresses of CUDC - 907 through clinical trials		0
Leukemia and Lymphoma Society [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contribution of fund from LLS amount					4,000,000
Royalty Obligation on successful progresses of CUDC - 907 through clinical trials	10,000,000
Roche's Application to TGA for Marketing Registration [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			650,000
FDA's [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	150,000	500,000
Contingent payments received			$10,000,000

Stock_Plans_and_Stock_Based_Co2

Stock Plans and Stock Based Compensation - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
	Jun. 02, 2014	Feb. 18, 2014	Jun. 30, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2010
	Jun. 02, 2014	Feb. 18, 2014	Jun. 30, 2014	Feb. 28, 2014	Plans	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2010
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based compensation, number of plans					2
Additional awards made under plans					0
Options granted					2,275,500
Options issued					1,040,000
Aggregate intrinsic value of employee options outstanding					$659,000
Intrinsic value of exercisable options					659,000
Weighted average grant-date fair values of stock options	$0.34	$1.20			$1.79	$2.27	$2.99
Unrecognized compensation cost, net of estimated forfeitures					4,720,000
Intrinsic values of employee stock options exercised					105,000	2,091,000	6,145,000
Fair values of vested stock options					2,907,000	2,716,000	2,525,000
Stock options granted	400,000	640,000	400,000	640,000	3,140,855	2,651,152	3,268,689
Stock option granted, per share			$1.75	$3.09	$2.65
Compensation expense related to employee and director stock option grants					392,945
Non-employee compensation expense, recognized expenses						351,089	355,222
Non-employee compensation expenses					80,866	-351,089	-355,222
Income tax benefits					0	0	0
Subject to Market Conditions [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Aggregate expense for grants					905,000
Amended and Restated 2010 Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares available for future purchase under ESPP					1,749,752
Company's maximum shares issue pursuant to awards granted					9,000,000
Expiration of option exercisable					10 years
Number of shares awarded per share under specified stock value					1.3
Options granted					2,040,500
Shares vested under the 2010 plan					1,000,500
Share based compensation arrangement vesting period, years					4 years
Options issued					1,040,000
Consecutive trading days					60 days
Amended and Restated 2010 Plan [Member] \| Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Price charged for stock based award					100.00%
2000 Stock Incentive Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average remaining contractual life of vested stock options					5 years 10 months 21 days
Non-Employee Directors [Member] \| Amended and Restated 2010 Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Options granted					235,000
Share based compensation, vesting period of 235000 options					1 year
Non-Employee Directors [Member] \| 2000 Stock Incentive Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, weighted average period for recognition, years					2 years 4 months 24 days
Consultant [Member] \| Amended and Restated 2010 Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Options granted					525,000
2000 Director Stock Option Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares available for future purchase under ESPP								0
Employee Stock Purchase Plan [Member] \| 2010 Employee Stock Purchase Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares available for future purchase under ESPP					500,000
Price charged for stock based award					85.00%
Compensation expense related to employee and director stock option grants					$25,604	$40,008	$72,833
Number of purchase periods per year					2
Shares issued under ESPP					325,314
Shares issued under ESPP during period					56,983
Shares available for future purchase under ESPP					174,686

Stock_Plans_and_Stock_Based_Co3

Stock Plans and Stock Based Compensation - Valuation Assumptions Used to Calculate Fair Value of Employee Options Awarded (Detail) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
	Jun. 02, 2014	Feb. 18, 2014	Jun. 30, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Expected life (years)	6 years	6 years
Risk-free interest rate	2.10%	1.90%			1.90%
Volatility	65.00%	70.00%
Dividends	0.00%	0.00%			0.00%	0.00%	0.00%
Number of options granted	400,000	640,000	400,000	640,000	3,140,855	2,651,152	3,268,689
Fair value per share	$0.34	$1.20			$1.79	$2.27	$2.99
Minimum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Risk-free interest rate						1.00%	1.00%
Volatility					70.00%	70.00%	74.00%
Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Risk-free interest rate						2.10%	1.20%
Volatility					71.00%	72.00%	76.00%
Employees [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Expected life (years)					6 years	6 years	6 years
Officers and Directors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Expected life (years)					7 years	7 years	6 years

Stock_Plans_and_Stock_Based_Co4

Stock Plans and Stock Based Compensation - Summary of Stock Option Activity (Detail) (USD $)	1 Months Ended		12 Months Ended
	Jun. 30, 2014	Feb. 28, 2014	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding, December 31, 2013 (6,884,869 exercisable at weighted average price of $2.44 per share)			10,077,805
Number of Shares, Granted			2,275,500
Number of Shares, Exercised			-114,812
Number of Shares, Cancelled			-918,874
Outstanding, December 31, 2014 (7,534,372 exercisable at weighted average price of $2.45 per share)			11,319,619
Number of Shares, Vested and unvested expected to vest			10,980,633
Weighted Average Exercise Price per Share, Beginning Balance			$2.79
Weighted Average Exercise Price per Share, Granted	$1.75	$3.09	$2.65
Weighted Average Exercise Price per Share, Exercised			$1.86
Weighted Average Exercise Price per Share, Cancelled			$4.11
Weighted Average Exercise Price per Share, Ending Balance			$2.66
Weighted Average Exercise Price per Share, Vested and unvested expected to vest			$2.66

Stock_Plans_and_Stock_Based_Co5

Stock Plans and Stock Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based payment award, number of exercisable shares	7,534,372	6,884,869
Share-based payment award, weighted average price	$2.45	$2.44

Stock_Plans_and_Stock_Based_Co6

Stock Plans and Stock Based Compensation - Summary of Compensation Expense Related to ESPP (Detail) (USD $)	0 Months Ended		12 Months Ended
	Jun. 02, 2014	Feb. 18, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense recognized under ESPP			$392,945
Expected term	6 years	6 years
Dividends	0.00%	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member] \| 2010 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense recognized under ESPP			$25,604	40,008	72,833
Expected term			6 months	6 months	6 months
Minimum risk-free interest rate			0.06%	0.08%	0.05%
Maximum risk-free interest rate			0.09%	0.10%	0.15%
Minimum volatility			55.00%	42.00%	42.00%
Maximum volatility			66.00%	66.00%	75.00%
Dividends			0.00%	0.00%	0.00%

Stock_Plans_and_Stock_Based_Co7

Stock Plans and Stock Based Compensation - Employee and Non-Employee Share Based Compensation Expense Allocation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation expense	$3,059,989	$3,002,241	$3,623,911
Research and Development Expenses [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation expense	671,063	879,052	1,075,134
General and Administrative Expenses [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation expense	$2,388,926	$2,123,189	$2,548,777

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment	$2,337,302	$2,359,084
Less-Accumulated depreciation and amortization	-1,929,564	-1,913,429
Property and equipment, net	407,738	445,655
Laboratory Equipment, Computers and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,963,017	1,941,588
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	62,621	62,621
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$311,664	$354,875

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$155,083	$141,522	$126,537
Wrote off gross assets and related accumulated depreciation	$139,000	$329,000	$418,000

Accrued_Liabilities_Accrued_Li

Accrued Liabilities - Accrued Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]
Accrued compensation	$1,386,226	$1,267,954
Professional fees	122,850	166,200
Accrued interest on debt	286,075	298,935
Other	212,548	178,390
Total	$2,007,699	$1,911,479

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	12 Months Ended
Debt - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt [Line Items]
Payment towards debt obligations	$8,901,330
Accrued interest on loan amount to Curis Royalty given by BioPharma under credit agreement	1,587,154
Debt, current portion net of issuance costs	5,709,985	2,610,174
Long-term debt	22,589,058	27,945,186
Debt issue costs, current	43,616	51,441
Debt issue costs, long-term	64,564	101,055
Debt issuance cost	108,180	152,496	421,715
Interest expense recognized related to loan	3,748,374	3,841,646	204,167
Other Current Assets [Member]
Debt [Line Items]
Debt issue costs, current	38,074	53,503
Debt issuance cost	43,616	51,441
Other Assets [Member]
Debt [Line Items]
Debt issue costs, long-term	75,729	105,105
Debt issuance cost	64,564	101,055
BioPharma-II [Member]
Debt [Line Items]
Debt issuance cost			215,000
Interest expense recognized related to loan	3,748,374	3,841,646	204,167
Curis Royalty [Member]
Debt [Line Items]
Long-term debt	22,589,058	27,945,186
Estimated fair value of principal portion of debt	28,710,000
Debt issuance cost			206,715
Curis Royalty [Member] \| BioPharma-II [Member]
Debt [Line Items]
Principal loan amount to Curis Royalty given by BioPharma under credit agreement			30,000,000
Interest rate on loan to Curis Royalty given by BioPharma under credit agreement			12.25%
Allocation of royalty payments received towards principal and interest subject to cap, cap amount for 2015	3,000,000
Percentage of loan that may be prepaid after January 01, 2017	105.00%
Accrued interest on loan amount to Curis Royalty given by BioPharma under credit agreement	286,075	298,935
Debt, current portion net of issuance costs	5,748,059
Long-term debt	22,664,787
Genentech Inc [Member]
Debt [Line Items]
Percentage of royalty rate decrease	2.00%
Genentech Inc [Member] \| Minimum [Member]
Debt [Line Items]
Percentage of royalty on net sales	5.00%
Royalty portion of annual worldwide net sales	150,000,000
Percentage of royalty	3.00%
Genentech Inc [Member] \| Maximum [Member]
Debt [Line Items]
Percentage of royalty on net sales	7.50%
Royalty portion of annual worldwide net sales	$600,000,000
Percentage of royalty	5.50%

Debt_Schedule_of_Debt_Issuance

Debt - Schedule of Debt Issuance Costs (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt [Line Items]
Total debt issuance costs	$108,180	$152,496	$421,715
Debt, current	5,748,059	2,663,677
Debt issue costs, current	-43,616	-51,441
Debt, current portion net of issuance costs	5,709,985	2,610,174
Debt, long-term	22,664,787	28,050,291
Debt issue costs, long-term	-64,564	-101,055
Long-term debt, net	22,589,058	27,945,186
Other Current Assets [Member]
Debt [Line Items]
Total debt issuance costs	43,616	51,441
Debt issue costs, current	-38,074	-53,503
Other Assets [Member]
Debt [Line Items]
Total debt issuance costs	64,564	101,055
Debt issue costs, long-term	($75,729)	($105,105)

Debt_Schedule_of_Future_Paymen

Debt - Schedule of Future Payments of Principal on Loan (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Less current portion, gross	($5,709,985)	($2,610,174)
Total long-term debt obligations, gross	22,589,058	27,945,186
Curis Royalty [Member]
Debt Instrument [Line Items]
Total long-term debt obligations, gross	22,589,058	27,945,186
Curis Royalty [Member] \| BioPharma-II [Member]
Debt Instrument [Line Items]
2015, Principal	5,748,059
2016, Principal	10,011,236
2017, Principal	12,653,551
Thereafter	0
Total payments	28,412,846
Less current portion, gross	-5,748,059
Total long-term debt obligations, gross	22,664,787
Total payments	$28,412,846

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2015
	sqft	Dec. 31, 2013	Licensors	Dec. 31, 2015
License Agreement [Line Items]
Area of lease property	24,529
Expiry of lease	28-Feb-18
Additional period for lease	5 years
Cash obligation for base rent over initial term	$4,401,000
Security deposit in form of letter of credit considered as restricted investment	166,487	180,364
Rent expense for operating lease	614,000	614,000	614,000
Shares of common stock issued	87,253,657	87,081,862
Number of university licensors			2
Issuance of common stock to licensors			964,000
Research and development	13,659,398	12,926,834	15,492,302
Cost of royalty revenues	339,578	197,796	176,482
In-process research and development			9,500,000
4 Maguire Road [Member] \| Letter of Credit [Member] \| Scenario, Forecast [Member]
License Agreement [Line Items]
Reduction in security deposit				13,877
Genentech IAP License [Member]
License Agreement [Line Items]
In-process research and development			9,500,000
License Agreement Terms [Member]
License Agreement [Line Items]
Shares of common stock issued			200,000
Issuance of common stock to licensors			964,000
Research and development	417,000	500,000	2,114,000
Financial Standby Letter of Credit [Member]
License Agreement [Line Items]
Original amount of security deposit to lessor on form of irrevocable letter of credit	$277,546
Minimum [Member]
License Agreement [Line Items]
Extension period for lease	1 year
Maximum [Member]
License Agreement [Line Items]
Extension period for lease	18 months

Commitments_Schedule_of_Operat

Commitments - Schedule of Operating Lease Commitments (Detail) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$651,000
2016	676,000
2017	700,000
2018	59,000
Total minimum payments	$2,086,000

Common_Stock_and_Warrant_Liabi2

Common Stock and Warrant Liability - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2010	Dec. 31, 2012	Jan. 27, 2010	Jul. 03, 2013	Jun. 13, 2011
Common Stock And Warrant Liability [Line Items]
Shares of common stock issued	87,253,657	87,081,862
ATM agreement resulting in gross proceeds	$872,537	$870,819
Issuance of registered direct offering, units					6,449,288
Registered direct offering, number of common stock per units					1
Registered direct offering, number of warrants per units					1
Direct offering purchase price per unit					2.52
Proceeds from registered direct offering of units, net of issuance costs			14,942,317
Aggregate number of shares of stock available to purchase using warrants	1,373,517				1,612,322
Warrants exercised	238,805
Expiration of warrants	27-Jan-15
Exercise price of warrants	$3.55
Term of warrants, years	5 years
Change in fair value	-716,786	-771,393
Sales Agreement [Member] \| Cowen [Member]
Common Stock And Warrant Liability [Line Items]
Common stock aggregate offering price						30,000,000
Common stock commission as percentage of gross sale price per share sold	3.00%
Reimbursement of expenses from offering	34,268
Shares of common stock issued		3,850,206
ATM agreement resulting in gross proceeds		16,887,036
Total offering expenses, including Cowen's commission		641,052
Common stock sold	0
Other Income [Member]
Common Stock And Warrant Liability [Line Items]
Change in fair value	716,786	771,393		2,257,130
Exercise of warrants to purchase common stock				237,301
Warrant liability decreased				615,859
Market Issuance Sales Agreement [Member] \| McNicoll Lewis And Vlak [Member]
Common Stock And Warrant Liability [Line Items]
Common stock aggregate offering price							20,000,000
Shares of common stock issued				210,879
ATM agreement resulting in gross proceeds				906,436
Total offering expenses, including Cowen's commission				$27,356
Termination date of ATM agreement	2013-06
Warrants Outstanding [Member]
Common Stock And Warrant Liability [Line Items]
Value of warrant in terms of percentage of stock					0.25

Common_Stock_and_Warrant_Liabi3

Common Stock and Warrant Liability - Estimated Fair Value of Warrants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common Stock And Warrant Liability [Line Items]
Fair value of the warrants			$615,859
Warrants Outstanding [Member]
Common Stock And Warrant Liability [Line Items]
Fair value of the warrants		$716,786	$1,488,179
Expected term	1 month 6 days	1 year 1 month 6 days	2 years 1 month 6 days
Risk-free interest rate	0.00%	0.16%	0.27%
Volatility	82.00%	65.00%	58.00%
Dividends	0.00%	0.00%	0.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
State income tax expense	$0	$0	$0
Federal income tax expense	0	0	0
Valuation Allowance	121,919,000	114,904,000
Expiration date of state research and experimentation credit carryforwards	Starting in 2019 through 2034
Net operating losses expiration year	2014
Beginning date of state research and experimentation credit carryforwards	2019
Expiration date of state research and experimentation credit carryforwards	2034
Unrecognized tax benefits	0	0
Uncertain tax position	0
Federal [Member]
Income Taxes [Line Items]
Operating loss	222,620,000
Federal [Member] \| Research [Member]
Income Taxes [Line Items]
Research and experimentation credit carryforwards	9,807,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss	49,202,000
State and Local Jurisdiction [Member] \| Research [Member]
Income Taxes [Line Items]
Research and experimentation credit carryforwards	3,644,000
Earliest Tax Year [Member]
Income Taxes [Line Items]
Years open to examination	1999
Latest Tax Year [Member]
Income Taxes [Line Items]
Years open to examination	2014
Massachusetts [Member] \| State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss	$9,857,000

Income_Taxes_Effective_Income_

Income Taxes - Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	34.00%	34.00%	34.00%
State income taxes, net of federal benefit	4.90%	5.20%	5.80%
Research and development tax credits	3.20%	8.50%	0.80%
Deferred compensation	-1.60%	0.80%	2.10%
Interest expense	-1.60%	-2.50%
Fair value of warrants	1.30%	2.10%
NOL expirations	-2.80%	-5.20%	-36.00%
Other	0.10%	0.10%	-1.70%
Net decrease in valuation allowance	-37.50%	-43.00%	-5.00%
Effective income tax rate	0.00%	0.00%	0.00%

Income_Taxes_Components_of_Def

Income Taxes - Components of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets:
Net operating loss carryforwards	$78,289	$72,446
Research and development tax credit carryforwards	12,212	11,588
Depreciation and amortization	3,591	3,891
Capitalized research and development expenditures	24,059	23,711
Impairment of investments	120	120
Stock options	3,534	2,723
Accrued expenses and other	114	118
Deferred interest expense		307
Total Gross Deferred Tax Asset	121,919	114,904
Valuation Allowance	-121,919	-114,904
Net Deferred Tax Asset	$0	$0

Income_Taxes_Classification_of

Income Taxes - Classification of Deferred Tax Asset (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets:
Current deferred tax assets	$39	$35
Non-current deferred tax assets	121,880	114,869
Valuation Allowance	-121,919	-114,904
Net Deferred Tax Asset	$0	$0

Related_Party_Transactions_Agr

Related Party Transactions - Agreement with Former Officer - Additional Information (Detail) (Mr. Passeri [Member], USD $)	0 Months Ended	12 Months Ended
	Jun. 02, 2014	Dec. 31, 2014
Mr. Passeri [Member]
Related Party Transaction [Line Items]
Compensation received	$100,000
Consulting agreement date	2-Jun-14
Consulting agreement term	1 year
Consulting service hours per month	120 hours
Consulting fees per month	32,500
Consulting agreement end date	1-Jun-15
Consulting agreement, recognized expenses		$197,833

Related_Party_Transactions_Agr1

Related Party Transactions - Agreement with Director - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Option	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Granted options, purchase an aggregate	2,275,500
Director [Member]
Related Party Transaction [Line Items]
Granted options, purchase an aggregate	125,000
Vesting period for options	4 years
Dr. Pienta [Member]
Related Party Transaction [Line Items]
Effective date of SAB agreement	13-Sep-06
Compensation received	$50,000
Consulting agreement date	1-Mar-12
Payment of cash consideration	$50,000	$72,258	$190,000
Number of stock options granted by directors	2

Related_Party_Transactions_Lic

Related Party Transactions - License Agreement with Former Officer - Additional Information (Detail) (Guangzhou BeBetter Medicine Technology Company Ltd. [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Guangzhou BeBetter Medicine Technology Company Ltd. [Member]
Related Party Transaction [Line Items]
Maximum financial support for GBMT	$400,000
Expenses of license agreement	$266,667	$0	$133,333

Retirement_Savings_Plan_Additi

Retirement Savings Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Matching contribution	$172	$145	$153

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Selected Quarterly Financial Information [Abstract]
Revenues	$1,992,699	$1,764,864	$4,801,285	$1,284,633	$1,524,137	$7,202,083	$5,404,377	$871,435	$9,843,481	$15,002,032	$16,971,991
(Loss) income from operations	-4,811,088	-4,753,031	-1,544,787	-4,753,343	-4,483,217	130,368	-706,196	-4,357,364	-15,862,249	-9,416,409	-18,619,807
Net loss	($5,688,870)	($5,580,143)	($1,895,785)	($5,563,936)	($4,198,032)	($1,867,838)	($1,293,848)	($4,962,294)	($18,728,734)	($12,322,012)	($16,416,907)
Net Loss per Common Share (Basic and Diluted)	($0.07)	($0.06)	($0.02)	($0.06)	($0.05)	($0.02)	($0.02)	($0.06)	($0.22)	($0.15)	($0.21)
Weighted Average Common Shares (Basic and Diluted)	86,010,499	86,004,857	85,963,836	85,917,592	85,741,278	82,456,708	81,128,475	80,096,650	85,974,535	82,339,493	79,059,153

Subsequent_Events_Collaboratio

Subsequent Events - Collaboration, License and Option Agreement with Aurigene Discovery Technologies, Ltd. - Additional Information (Detail) (Subsequent Event [Member], USD $)	0 Months Ended	1 Months Ended
	Feb. 06, 2015	Jan. 31, 2015
Subsequent Event [Line Items]
Percentage of royalties on net sales in territories	3.00%
Aurigene Discovery Technologies, Ltd. [Member]
Subsequent Event [Line Items]
Common stock issued, share		17,120,131
Percentage of common stock outstanding		19.90%
Aurigene Discovery Technologies, Ltd. [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Percentage of royalties on net sales in territories		10.00%
Aurigene Discovery Technologies, Ltd. [Member] \| Program One [Member]
Subsequent Event [Line Items]
Collaboration agreement expenses, approval and commercial milestones		42,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program One [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Collaboration agreement payment per program		52,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Two [Member]
Subsequent Event [Line Items]
Collaboration agreement expenses, approval and commercial milestones		42,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Two [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Collaboration agreement payment per program		52,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Three [Member]
Subsequent Event [Line Items]
Collaboration agreement expenses, approval and commercial milestones		42,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Three [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Collaboration agreement payment per program		50,000,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Four [Member]
Subsequent Event [Line Items]
Collaboration agreement expenses, approval and commercial milestones		42,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Four [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Collaboration agreement payment per program		50,000,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Thereafter [Member]
Subsequent Event [Line Items]
Collaboration agreement expenses, approval and commercial milestones		87,500,000
Aurigene Discovery Technologies, Ltd. [Member] \| Program Thereafter [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Collaboration agreement payment per program		140,500,000

Subsequent_Events_Termination_

Subsequent Events - Termination and Transition Agreement Debiopharm - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Feb. 06, 2015
Subsequent Event [Line Items]
Milestone payments term	The Company has agreed to make each of the following one-time payments to Debiopharm (i) $3,000,000 within 30 days after the first dosing of the first patient in the first Phase 3 clinical trial of Debio 0932; and (ii) $10,000,000 within 30 days after receipt of the first marketing approval for Debio 0932 in the United States of America or any specified major European market (whichever occurs first);
Subsequent Event [Member]
Subsequent Event [Line Items]
Up-front drug product payment		$750,000
Termination of the agreement		15 days
Percentage of royalty on net sales		3.00%
Royalties receives from third party		10.00%
Percentage of non-royalty sublicense payments		15.00%
Non-royalty sublicense payments		20,000,000
Subsequent Event [Member] \| United States of America [Member]
Subsequent Event [Line Items]
One-time payments		10,000,000
Subsequent Event [Member] \| Major Specified European Market [Member]
Subsequent Event [Line Items]
One-time payments		10,000,000
Subsequent Event [Member] \| Phase 3 Clinical Trial [Member]
Subsequent Event [Line Items]
One-time payments		$3,000,000